≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

Pseudomembranous colitis

Endpoint Browser

COLITENTER

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — K52.80#
  • Cause of death: ICD-10 — K52.80#

2 out of 7 registries used, show all original rules.

317

4. Check minimum number of events

None

317

5. Include endpoints

None

317

6. Filter based on genotype QC (FinnGen only)

304

Control definitions (FinnGen only)

Control exclude
K11_ENERCOLNONINF

Extra metadata

First used in FinnGen datafreeze
DF2
Parent code in ICD-10
K52
Name in latin
Colitis [haemorrhagica] ex usu antibioticorum

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 304 199 105
Unadjusted period prevalence (%) 0.06 0.07 0.05
Median age at first event (years) 49.45 45.27 57.38

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
317
Matched controls
3170
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
K52.80
ICD-10 Finland
(Hemorrhagic) colitis caused by antibiotics
+∞
307.7
317
*
A07EC02
ATC
mesalazine; oral, rectal
85.9
145.5
78
12
K52.9
ICD-10 Finland
Noninfective gastroenteritis and colitis, unspecified
55.9
108.9
63
14
A07EA06
ATC
budesonide; oral, local oral
47.3
91.8
55
14
A04.7
ICD-10 Finland
Enterocolitis due to Clostridium difficile
22.9
78.1
60
32
K52.88
ICD-10 Finland
Other specified noninfective gastroenteritis and colitis
124.5
72.7
76
8
K51.9
ICD-10 Finland
Ulcerative colitis, unspecified
673.8
58.6
56
*
208
Kela drug reimbursment
Ulcerative colitis and Crohn's disease
+∞
53.7
50
*
UJF32
NOMESCO Finland
Coloscopy
5.3
47.2
147
445
P01AB01
ATC
metronidazole; oral, rectal
5.0
41.9
215
941
K51.5
ICD-10 Finland
Left sided colitis
+∞
39.4
37
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
4.8
38.3
121
362
C10AC01
ATC
colestyramine; oral
14.1
34.6
33
26
L04AX01
ATC
azathioprine; systemic
12.6
34.2
35
31
K51.8
ICD-10 Finland
Other ulcerative colitis
307.2
28.2
28
*
J01MA02
ATC
ciprofloxacin; systemic
3.2
23.3
168
823
A07AA09
ATC
vancomycin; oral
28.4
23.1
31
12
UJF30
NOMESCO Finland
Ileoscopy through colon
4.8
22.0
55
132
A07EC01
ATC
sulfasalazine; oral, rectal
4.9
19.0
46
107
L01BA01
ATC
methotrexate; systemic
8.2
19.0
26
34
H02AB06
ATC
prednisolone; systemic
2.8
17.8
190
1102
A07EA02
ATC
hydrocortisone; rectal
44.8
17.5
21
5
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
4.6
17.2
44
107
K59.1
ICD-10 Finland
Functional diarrhoea
5.1
17.1
38
82
A07DA03
ATC
loperamide; oral
7.2
16.8
26
39
K50.0
ICD-10 Finland
Crohn disease of small intestine
+∞
15.8
15
*
K50.8
ICD-10 Finland
Other Crohn disease
+∞
15.8
15
*
UJF12
NOMESCO Finland
Enteroscopy through intestinal stoma
+∞
15.8
15
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.7
15.5
117
561
J01FF01
ATC
clindamycin; systemic
2.7
14.7
114
551
UJF14
NOMESCO Finland
Enteroscopy of ileoanal anastomosis
156.9
14.6
15
*
A06AC01
ATC
ispaghula (psylla seeds); oral
2.6
13.7
112
553
K51.0
ICD-10 Finland
Ulcerative (chronic) pancolitis
+∞
13.6
13
*
K51.1
ICD-10 Finland
Ulcerative (chronic) ileocolitis
+∞
13.6
13
*
K50.9
ICD-10 Finland
Crohn disease, unspecified
146.0
13.6
14
*
H02AB07
ATC
prednisone; oral
3.0
12.9
65
249
K51.2
ICD-10 Finland
Ulcerative (chronic) proctitis
+∞
12.6
12
*
N06AA09
ATC
amitriptyline; systemic
3.3
11.6
47
157
K50.1
ICD-10 Finland
Crohn disease of large intestine
+∞
11.5
11
*
K51
ICD-10 Finland
Ulcerative colitis
+∞
11.5
11
*
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.2
10.9
137
804
N02AX02
ATC
tramadol; systemic, rectal
2.2
10.5
156
973
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
3.8
10.5
33
93
326
Kela drug reimbursment
Adalimumab, golimumab, infliximab and ustekinumab (intestinal diseases)
+∞
10.5
10
*
K51.3
ICD-10 Finland
Ulcerative (chronic) rectosigmoiditis
+∞
10.5
10
*
J01MA12
ATC
levofloxacin; systemic
2.5
10.4
76
351
A02BC03
ATC
lansoprazole; oral
2.3
10.2
111
610
A02BC01
ATC
omeprazole; systemic
2.3
10.2
108
587
J01FA06
ATC
roxithromycin; oral
2.1
9.9
148
921
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
3.1
9.5
43
154
N03AX12
ATC
[U] gabapentin; oral
2.5
9.4
66
297
5562A
ICD-9 Finland
Idiopathic proctocolitis, Ulcerative (chronic) proctitis
+∞
9.4
9
*
Z01.8
ICD-10 Finland
Other specified special examinations
2.3
9.2
82
412
UJF92
NOMESCO Finland
Capsular endoscopy
16.2
9.1
14
9
K58.0
ICD-10 Finland
Irritable bowel syndrome with diarrhoea
3.8
8.9
28
79
N05CD07
ATC
temazepam; oral
2.7
8.9
52
214
A07AA02
ATC
nystatin; oral
3.5
8.7
31
95
M13.9
ICD-10 Finland
Arthritis, unspecified
3.3
8.6
34
112
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
3.4
8.2
31
99
A46
ICD-10 Finland
Erysipelas
2.5
8.1
58
263
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.4
8.0
30
95
K56.6
ICD-10 Finland
Other and unspecified intestinal obstruction
6.4
8.0
20
33
N06AB04
ATC
citalopram; systemic
2.2
7.9
82
437
A04.9
ICD-10 Finland
Bacterial intestinal infection, unspecified
15.5
7.8
12
8
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.5
7.7
51
222
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
2.6
7.6
47
198
A01AB09
ATC
miconazole; local oral
2.7
7.5
42
168
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.9
7.5
36
133
T36
ICD-10 Finland
Poisoning by systemic antibiotics
4.2
7.5
20
50
K56.7
ICD-10 Finland
Ileus, unspecified
8.7
7.4
15
18
5561A
ICD-9 Finland
Idiopathic proctocolitis, Ulcerative (chronic) ileocolitis
+∞
7.3
7
*
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
2.5
7.3
49
215
A02BX02
ATC
sucralfate; oral
4.1
7.3
20
51
A06AD11
ATC
lactulose; oral
2.3
7.2
61
298
K92.1
ICD-10 Finland
Melaena
3.6
7.0
23
67
L04AB04
ATC
adalimumab; parenteral
8.6
6.9
14
17
A02BA02
ATC
ranitidine; systemic
2.1
6.9
75
405
L01BB02
ATC
mercaptopurine; oral
41.0
6.8
8
*
D94
ICPC
Chronic enteritis/ulcerative colitis
41.0
6.8
8
*
L04AX03
ATC
methotrexate; systemic
2.6
6.7
39
160
J02AC01
ATC
fluconazole; systemic
1.9
6.6
135
903
N03AE01
ATC
clonazepam; systemic
3.2
6.6
26
85
WX002
NOMESCO Finland
Sedation and analgesia
2.2
6.6
64
330
TPH04
NOMESCO Finland
Cathetrisation of vein
2.1
6.6
75
412
C03CA01
ATC
furosemide; systemic
1.9
6.4
107
670
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
2.8
6.4
32
121
P01BA02
ATC
hydroxychloroquine; oral
2.7
6.3
35
140
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.4
6.3
44
197
A07EA01
ATC
prednisolone; oral, rectal
+∞
6.3
6
*
5568X
ICD-9 Finland
Idiopathic proctocolitis, Other ulcerative colitis
+∞
6.3
6
*
JFH30
NOMESCO Finland
Total colectomy, mucosal proctectomy and ileoanal anastomosis without ileostomy
+∞
6.3
6
*
ZX120
NOMESCO Finland
Intravenous
2.6
6.3
39
165
SPAT1263
SPAT
Sampling
1.8
6.2
132
891
G01AF05
ATC
econazole; vaginal
2.8
6.2
32
123
K56.5
ICD-10 Finland
Intestinal adhesions [bands] with obstruction
7.9
6.2
13
17
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
3.2
6.2
24
78
H02AB04
ATC
methylprednisolone; systemic
2.2
6.1
55
274
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.0
6.1
73
406
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
3.7
6.1
19
53
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.6
6.1
20
58
E000003, ,
ATC
3.5
6.1
21
63
A02BA04
ATC
nizatidine; systemic
2.8
6.1
31
118
A02BC02
ATC
pantoprazole; systemic
1.9
6.0
217
1710

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Outpatient Visit
OP [9202]
7.6e-01
1.0e+00
1.3e+00
4.6e+00
1.5e+00
1.2e+00
8.5e-01
cases:66.77%
controls:48.47%
cases:55.59%
controls:30.70%
cases:23.96%
controls:7.57%
cases:27.80%
controls:0.38%
cases:25.89%
controls:7.12%
cases:62.67%
controls:33.89%
cases:81.98%
controls:66.02%
209
1517
104
1613
174
961
139
2169
75
237
238
2893
87
12
226
3118
80
223
229
2907
188
1052
112
2052
232
1972
51
1015
Internal Medicine
11 [38004456]
1.2e+00
1.8e+00
2.7e+00
—
2.6e+00
1.7e+00
1.1e+00
cases:43.13%
controls:19.20%
cases:36.74%
controls:9.14%
cases:21.09%
controls:1.73%
—
—
cases:16.50%
controls:1.47%
cases:37.00%
controls:9.38%
cases:46.64%
controls:21.83%
135
601
178
2529
115
286
198
2844
66
54
247
3076
—
51
46
258
3084
111
291
189
2813
132
652
151
2335
Office Visit
OMOP4822458 [581477]
1.1e+00
1.5e+00
3.4e+00
1.0e+50
2.8e+00
1.1e+00
1.0e+00
cases:16.29%
controls:6.20%
cases:11.50%
controls:2.75%
cases:6.07%
controls:0.22%
cases:5.11%
controls:0.00%
cases:4.21%
controls:0.26%
cases:7.33%
controls:2.45%
cases:19.08%
controls:7.87%
51
194
262
2936
36
86
277
3044
19
7
294
3123
16
0
297
3130
13
8
296
3122
22
76
278
3028
54
235
229
2752
metronidazole; oral, rectal
P01AB01 [21604857]
1.3e+00
2.3e+00
—
1.0e+50
4.3e+00
1.8e+00
1.1e+00
cases:16.61%
controls:5.14%
cases:11.18%
controls:1.28%
—
—
cases:3.51%
controls:0.00%
cases:19.42%
controls:0.32%
cases:9.33%
controls:1.64%
cases:14.84%
controls:5.66%
52
161
261
2969
35
40
278
3090
—
11
0
302
3130
60
10
249
3120
28
51
272
3053
42
169
241
2818
Gastroenterology
10 [38004455]
2.4e+00
2.8e+00
—
1.0e+50
—
3.3e+00
2.0e+00
cases:9.90%
controls:0.99%
cases:10.22%
controls:0.70%
—
—
cases:12.46%
controls:0.00%
—
—
cases:12.67%
controls:0.52%
cases:16.61%
controls:2.61%
31
31
282
3099
32
22
281
3108
—
39
0
274
3130
—
38
16
262
3088
47
78
236
2909
prednisolone; oral, parenteral
H02AB06 [21602734]
1.4e+00
1.8e+00
2.2e+00
—
2.1e+00
1.6e+00
1.3e+00
cases:15.97%
controls:4.57%
cases:11.82%
controls:2.08%
cases:3.51%
controls:0.38%
—
—
cases:3.88%
controls:0.48%
cases:11.33%
controls:2.48%
cases:21.91%
controls:7.33%
50
143
263
2987
37
65
276
3065
11
12
302
3118
—
12
15
297
3115
34
77
266
3027
62
219
221
2768
prednisolone
A07EA01 [21600653]
1.4e+00
1.8e+00
2.2e+00
—
2.1e+00
1.6e+00
1.3e+00
cases:15.97%
controls:4.57%
cases:11.82%
controls:2.08%
cases:3.51%
controls:0.38%
—
—
cases:3.88%
controls:0.48%
cases:11.33%
controls:2.48%
cases:21.91%
controls:7.37%
50
143
263
2987
37
65
276
3065
11
12
302
3118
—
12
15
297
3115
34
77
266
3027
62
220
221
2767
Upper gastrointestinal surgery
106 [44777669]
1.5e+00
1.8e+00
2.3e+00
1.0e+50
2.5e+00
1.2e+00
1.2e+00
cases:12.14%
controls:3.13%
cases:9.58%
controls:1.76%
cases:3.51%
controls:0.35%
cases:4.47%
controls:0.00%
cases:1.94%
controls:0.16%
cases:4.67%
controls:1.48%
cases:16.61%
controls:5.79%
38
98
275
3032
30
55
283
3075
11
11
302
3119
14
0
299
3130
6
5
303
3125
14
46
286
3058
47
173
236
2814
Coloscopy
UJF32 [2001305029]
2.0e+00
2.6e+00
1.0e+50
1.0e+50
—
3.6e+00
1.4e+00
cases:7.67%
controls:1.15%
cases:4.79%
controls:0.38%
cases:1.92%
controls:0.00%
cases:5.11%
controls:0.00%
—
—
cases:9.33%
controls:0.29%
cases:8.83%
controls:2.28%
24
36
289
3094
15
12
298
3118
6
0
307
3130
16
0
297
3130
—
28
9
272
3095
25
68
258
2919
Psychiatry
26 [38004469]
1.6e+00
1.6e+00
1.7e+00
—
1.9e+00
1.4e+00
1.1e+00
cases:10.54%
controls:2.40%
cases:6.07%
controls:1.34%
cases:2.56%
controls:0.48%
—
—
cases:2.59%
controls:0.38%
cases:6.33%
controls:1.58%
cases:10.60%
controls:3.92%
33
75
280
3055
19
42
294
3088
8
15
305
3115
—
8
12
301
3118
19
49
281
3055
30
117
253
2870
Emergency Room Visit
ER [9203]
6.9e-01
1.4e+00
2.7e+00
—
2.3e+00
1.2e+00
9.3e-01
cases:39.30%
controls:24.50%
cases:32.59%
controls:10.77%
cases:21.41%
controls:1.82%
—
—
cases:9.06%
controls:0.96%
cases:28.67%
controls:10.50%
cases:54.77%
controls:32.41%
123
767
190
2363
102
337
211
2793
67
57
246
3073
—
28
30
281
3100
86
326
214
2778
155
968
128
2019
fluconazole; oral, parenteral
J02AC01 [21603080]
1.0e+00
1.3e+00
2.5e+00
—
2.3e+00
1.2e+00
7.6e-01
cases:16.29%
controls:6.39%
cases:7.99%
controls:2.36%
cases:2.24%
controls:0.19%
—
—
cases:1.94%
controls:0.19%
cases:7.67%
controls:2.38%
cases:14.84%
controls:7.57%
51
200
262
2930
25
74
288
3056
7
6
306
3124
—
6
6
303
3124
23
74
277
3030
42
226
241
2761
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
1.4e+00
2.1e+00
2.6e+00
—
—
1.7e+00
1.3e+00
cases:16.61%
controls:4.70%
cases:9.58%
controls:1.34%
cases:2.88%
controls:0.22%
—
—
—
—
cases:7.33%
controls:1.39%
cases:17.31%
controls:5.29%
52
147
261
2983
30
42
283
3088
9
7
304
3123
—
—
22
43
278
3061
49
158
234
2829
General Practice
1 [38004446]
9.1e-01
1.3e+00
2.3e+00
1.0e+50
2.7e+00
1.1e+00
6.5e-01
cases:16.29%
controls:7.28%
cases:10.22%
controls:3.07%
cases:7.67%
controls:0.80%
cases:11.50%
controls:0.00%
cases:8.09%
controls:0.58%
cases:11.67%
controls:4.25%
cases:20.14%
controls:11.68%
51
228
262
2902
32
96
281
3034
24
25
289
3105
36
0
277
3130
25
18
284
3112
35
132
265
2972
57
349
226
2638
Inpatient Hospital
21 [8717]
6.6e-01
1.4e+00
2.5e+00
—
2.4e+00
1.1e+00
7.6e-01
cases:50.48%
controls:34.57%
cases:38.34%
controls:13.48%
cases:23.00%
controls:2.40%
—
—
cases:16.50%
controls:1.73%
cases:31.00%
controls:12.73%
cases:52.65%
controls:34.21%
158
1082
155
2048
120
422
193
2708
72
75
241
3055
—
51
54
258
3076
93
395
207
2709
149
1022
134
1965
Infectious Disease
44 [38004484]
1.6e+00
2.0e+00
—
1.0e+50
—
2.7e+00
2.0e+00
cases:2.88%
controls:0.61%
cases:2.56%
controls:0.35%
—
—
cases:2.56%
controls:0.00%
—
—
cases:2.33%
controls:0.16%
cases:5.65%
controls:0.77%
9
19
304
3111
8
11
305
3119
—
8
0
305
3130
—
7
5
293
3099
16
23
267
2964
azathioprine; oral, parenteral
L04AX01 [21603927]
2.7e+00
2.1e+00
—
—
—
2.4e+00
2.6e+00
cases:3.83%
controls:0.26%
cases:1.60%
controls:0.19%
—
—
—
—
—
—
cases:2.00%
controls:0.19%
cases:2.12%
controls:0.17%
12
8
301
3122
5
6
308
3124
—
—
—
6
6
294
3098
6
5
277
2982
Pharmacy visit
OMOP4822462 [581458]
1.2e+00
9.8e-01
1.7e+00
1.6e+00
1.2e+00
8.6e-01
1.1e+00
cases:96.81%
controls:90.45%
cases:88.82%
controls:74.95%
cases:73.48%
controls:33.13%
cases:7.67%
controls:1.66%
cases:61.49%
controls:33.16%
cases:88.33%
controls:76.19%
cases:97.53%
controls:93.04%
303
2831
10
299
278
2346
35
784
230
1037
83
2093
24
52
289
3078
190
1038
119
2092
265
2365
35
739
276
2779
7
208
General Surgery
2 [38004447]
9.1e-01
1.1e+00
2.1e+00
1.0e+50
1.9e+00
6.4e-01
8.4e-01
cases:39.94%
controls:21.05%
cases:18.21%
controls:7.22%
cases:8.63%
controls:1.15%
cases:8.31%
controls:0.00%
cases:5.83%
controls:0.89%
cases:14.33%
controls:8.09%
cases:36.40%
controls:19.79%
125
659
188
2471
57
226
256
2904
27
36
286
3094
26
0
287
3130
18
28
291
3102
43
251
257
2853
103
591
180
2396
ispaghula (psylla seeds); oral
A06AC01 [21600555]
1.9e+00
2.2e+00
—
—
-1.0e+50
1.8e+00
1.5e+00
cases:5.75%
controls:0.93%
cases:3.83%
controls:0.45%
—
—
—
—
cases:0.00%
controls:0.26%
cases:4.00%
controls:0.68%
cases:9.54%
controls:2.38%
18
29
295
3101
12
14
301
3116
—
—
0
8
309
3122
12
21
288
3083
27
71
256
2916
Rheumatology
66 [38004491]
1.4e+00
2.3e+00
—
—
—
1.8e+00
1.5e+00
cases:5.11%
controls:1.28%
cases:4.79%
controls:0.48%
—
—
—
—
—
—
cases:3.67%
controls:0.61%
cases:8.48%
controls:2.01%
16
40
297
3090
15
15
298
3115
—
—
—
11
19
289
3085
24
60
259
2927
Outpatient Hospital
22 [8756]
7.4e-01
1.2e+00
1.8e+00
1.0e+50
1.4e+00
9.7e-01
7.6e-01
cases:38.66%
controls:23.07%
cases:22.36%
controls:8.12%
cases:6.71%
controls:1.15%
cases:8.31%
controls:0.00%
cases:3.56%
controls:0.89%
cases:17.67%
controls:7.51%
cases:40.28%
controls:24.04%
121
722
192
2408
70
254
243
2876
21
36
292
3094
26
0
287
3130
11
28
298
3102
53
233
247
2871
114
718
169
2269
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
4.2e-01
8.7e-01
2.2e+00
—
2.1e+00
9.3e-01
6.5e-01
cases:5.11%
controls:3.42%
cases:6.39%
controls:2.78%
cases:4.15%
controls:0.48%
—
—
cases:4.85%
controls:0.61%
cases:7.33%
controls:3.03%
cases:19.43%
controls:11.15%
16
107
297
3023
20
87
293
3043
13
15
300
3115
—
15
19
294
3111
22
94
278
3010
55
333
228
2654
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.8e+00
1.9e+00
—
—
—
1.9e+00
1.2e+00
cases:8.95%
controls:1.53%
cases:4.79%
controls:0.77%
—
—
—
—
—
—
cases:2.67%
controls:0.42%
cases:8.48%
controls:2.78%
28
48
285
3082
15
24
298
3106
—
—
—
8
13
292
3091
24
83
259
2904
Other and unspecified abdominal pain
R10.4 [45568113]
1.4e+00
1.8e+00
2.5e+00
—
—
1.1e+00
9.9e-01
cases:10.22%
controls:2.65%
cases:6.39%
controls:1.12%
cases:1.92%
controls:0.16%
—
—
—
—
cases:4.00%
controls:1.42%
cases:10.25%
controls:4.05%
32
83
281
3047
20
35
293
3095
6
5
307
3125
—
—
12
44
288
3060
29
121
254
2866
lansoprazole; oral
A02BC03 [21600098]
9.9e-01
1.3e+00
1.3e+00
—
2.2e+00
1.3e+00
8.7e-01
cases:11.18%
controls:4.47%
cases:7.67%
controls:2.14%
cases:1.60%
controls:0.45%
—
—
cases:2.59%
controls:0.29%
cases:7.33%
controls:2.16%
cases:12.01%
controls:5.42%
35
140
278
2990
24
67
289
3063
5
14
308
3116
—
8
9
301
3121
22
67
278
3037
34
162
249
2825
Flexible sigmoidoscopy with biopsy
UJF45 [2001305031]
2.0e+00
2.3e+00
—
1.0e+50
—
—
2.2e+00
cases:3.19%
controls:0.45%
cases:1.92%
controls:0.19%
—
—
cases:2.24%
controls:0.00%
—
—
—
—
cases:2.47%
controls:0.27%
10
14
303
3116
6
6
307
3124
—
7
0
306
3130
—
—
7
8
276
2979
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.7e+00
1.6e+00
—
—
—
1.8e+00
1.3e+00
cases:6.07%
controls:1.21%
cases:4.47%
controls:0.89%
—
—
—
—
—
—
cases:4.67%
controls:0.77%
cases:7.77%
controls:2.31%
19
38
294
3092
14
28
299
3102
—
—
—
14
24
286
3080
22
69
261
2918
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
2.1e+00
—
1.0e+50
1.0e+50
—
2.4e+00
1.9e+00
cases:5.43%
controls:0.70%
—
—
cases:5.75%
controls:0.00%
cases:7.67%
controls:0.00%
—
—
cases:3.67%
controls:0.35%
cases:9.54%
controls:1.51%
17
22
296
3108
—
18
0
295
3130
24
0
289
3130
—
11
11
289
3093
27
45
256
2942
oxycodone; oral, parenteral
N02AA05 [21604260]
—
2.3e+00
—
—
—
2.4e+00
1.7e+00
—
—
cases:2.56%
controls:0.26%
—
—
—
—
—
—
cases:3.00%
controls:0.29%
cases:4.95%
controls:0.97%
—
8
8
305
3122
—
—
—
9
9
291
3095
14
29
269
2958
methotrexate; oral, parenteral
L04AX03 [21603929]
1.4e+00
1.6e+00
—
—
1.5e+00
1.6e+00
1.7e+00
cases:4.47%
controls:1.09%
cases:4.15%
controls:0.86%
—
—
—
—
cases:2.27%
controls:0.51%
cases:4.00%
controls:0.87%
cases:6.01%
controls:1.17%
14
34
299
3096
13
27
300
3103
—
—
7
16
302
3114
12
27
288
3077
17
35
266
2952
methotrexate
L01BA01 [21601423]
1.4e+00
1.6e+00
—
—
1.5e+00
1.6e+00
1.7e+00
cases:4.47%
controls:1.09%
cases:4.15%
controls:0.86%
—
—
—
—
cases:2.27%
controls:0.51%
cases:4.00%
controls:0.87%
cases:6.01%
controls:1.17%
14
34
299
3096
13
27
300
3103
—
—
7
16
302
3114
12
27
288
3077
17
35
266
2952
Diverticular disease of large intestine without perforation or abscess
K57.3 [45567316]
1.6e+00
2.5e+00
—
—
—
2.1e+00
6.2e-01
cases:3.83%
controls:0.83%
cases:2.56%
controls:0.22%
—
—
—
—
—
—
cases:2.00%
controls:0.26%
cases:2.83%
controls:1.54%
12
26
301
3104
8
7
305
3123
—
—
—
6
8
294
3096
8
46
275
2941
Pulmonary Disease
29 [38004472]
7.1e-01
1.4e+00
2.3e+00
—
1.5e+00
1.3e+00
9.8e-01
cases:9.27%
controls:4.79%
cases:8.95%
controls:2.30%
cases:4.15%
controls:0.45%
—
—
cases:1.62%
controls:0.35%
cases:7.33%
controls:2.13%
cases:13.43%
controls:5.52%
29
150
284
2980
28
72
285
3058
13
14
300
3116
—
5
11
304
3119
22
66
278
3038
38
165
245
2822
Thorax X-ray examination
GD1AA [2001303617]
1.1e+00
1.7e+00
—
—
—
1.6e+00
1.3e+00
cases:4.47%
controls:1.53%
cases:3.83%
controls:0.70%
—
—
—
—
—
—
cases:4.67%
controls:1.00%
cases:12.72%
controls:3.68%
14
48
299
3082
12
22
301
3108
—
—
—
14
31
286
3073
36
110
247
2877
sulfasalazine; oral, rectal
A07EC01 [21600663]
1.9e+00
1.5e+00
—
—
—
1.9e+00
1.7e+00
cases:4.47%
controls:0.70%
cases:2.24%
controls:0.51%
—
—
—
—
—
—
cases:3.67%
controls:0.55%
cases:4.59%
controls:0.87%
14
22
299
3108
7
16
306
3114
—
—
—
11
17
289
3087
13
26
270
2961
Other seropositive rheumatoid arthritis
M05.8 [45538634]
1.6e+00
2.0e+00
—
—
—
1.8e+00
1.4e+00
cases:3.19%
controls:0.67%
cases:2.88%
controls:0.38%
—
—
—
—
—
—
cases:2.67%
controls:0.45%
cases:3.18%
controls:0.84%
10
21
303
3109
9
12
304
3118
—
—
—
8
14
292
3090
9
25
274
2962
cefalexin; oral
J01DB01 [21602870]
5.3e-01
1.1e+00
2.2e+00
—
1.0e+00
7.7e-01
6.8e-01
cases:35.46%
controls:24.38%
cases:21.41%
controls:8.66%
cases:7.35%
controls:0.83%
—
—
cases:2.59%
controls:0.93%
cases:17.00%
controls:8.70%
cases:42.40%
controls:27.25%
111
763
202
2367
67
271
246
2859
23
26
290
3104
—
8
29
301
3101
51
270
249
2834
120
814
163
2173
loperamide; oral
A07DA03 [21600646]
2.2e+00
—
—
—
—
—
3.0e+00
cases:4.79%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:6.01%
controls:0.30%
15
17
298
3113
—
—
—
—
—
17
9
266
2978
loperamide oxide; oral
A07DA05 [21600648]
2.2e+00
—
—
—
—
—
3.0e+00
cases:4.79%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:6.01%
controls:0.30%
15
17
298
3113
—
—
—
—
—
17
9
266
2978
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
1.1e+00
1.5e+00
1.7e+00
—
—
1.5e+00
1.2e+00
cases:12.78%
controls:4.63%
cases:8.31%
controls:2.04%
cases:1.92%
controls:0.35%
—
—
—
—
cases:8.33%
controls:2.03%
cases:17.31%
controls:6.09%
40
145
273
2985
26
64
287
3066
6
11
307
3119
—
—
25
63
275
3041
49
182
234
2805
Neurology
13 [38004458]
7.8e-01
8.8e-01
1.8e+00
—
—
1.0e+00
6.3e-01
cases:13.10%
controls:6.45%
cases:6.71%
controls:2.91%
cases:2.24%
controls:0.38%
—
—
—
—
cases:9.00%
controls:3.41%
cases:15.55%
controls:8.91%
41
202
272
2928
21
91
292
3039
7
12
306
3118
—
—
27
106
273
2998
44
266
239
2721
citalopram; oral, parenteral
N06AB04 [21604712]
1.0e+00
1.3e+00
2.1e+00
—
1.3e+00
1.6e+00
1.1e+00
cases:7.99%
controls:2.97%
cases:5.43%
controls:1.60%
cases:1.60%
controls:0.19%
—
—
cases:1.94%
controls:0.51%
cases:7.00%
controls:1.51%
cases:9.54%
controls:3.28%
25
93
288
3037
17
50
296
3080
5
6
308
3124
—
6
16
303
3114
21
47
279
3057
27
98
256
2889
Erysipelas
A46 [45561706]
1.6e+00
2.2e+00
—
—
—
1.9e+00
1.2e+00
cases:2.88%
controls:0.61%
cases:2.88%
controls:0.32%
—
—
—
—
—
—
cases:1.67%
controls:0.26%
cases:5.30%
controls:1.64%
9
19
304
3111
9
10
304
3120
—
—
—
5
8
295
3096
15
49
268
2938
calcium (different salts in combination); oral
A12AA20 [21600872]
1.1e+00
1.4e+00
1.3e+00
—
6.0e-01
1.3e+00
1.2e+00
cases:11.18%
controls:3.87%
cases:10.54%
controls:2.94%
cases:1.92%
controls:0.51%
—
—
cases:1.62%
controls:0.89%
cases:11.00%
controls:3.16%
cases:18.37%
controls:6.53%
35
121
278
3009
33
92
280
3038
6
16
307
3114
—
5
28
304
3102
33
98
267
3006
52
195
231
2792
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.6e+00
2.3e+00
—
—
—
—
1.1e+00
cases:5.75%
controls:1.21%
cases:3.83%
controls:0.42%
—
—
—
—
—
—
—
—
cases:5.65%
controls:1.87%
18
38
295
3092
12
13
301
3117
—
—
—
—
16
56
267
2931
venlafaxine; oral
N06AX16 [21604745]
1.7e+00
1.6e+00
—
—
—
1.8e+00
1.5e+00
cases:3.83%
controls:0.70%
cases:2.24%
controls:0.48%
—
—
—
—
—
—
cases:2.67%
controls:0.45%
cases:4.95%
controls:1.21%
12
22
301
3108
7
15
306
3115
—
—
—
8
14
292
3090
14
36
269
2951
esomeprazole; oral, parenteral
A02BC05 [21600100]
1.2e+00
1.6e+00
—
—
1.6e+00
1.2e+00
8.8e-01
cases:12.14%
controls:3.99%
cases:9.90%
controls:2.17%
—
—
—
—
cases:2.59%
controls:0.54%
cases:8.33%
controls:2.58%
cases:14.49%
controls:6.56%
38
125
275
3005
31
68
282
3062
—
—
8
17
301
3113
25
80
275
3024
41
196
242
2791
pantoprazole; oral, parenteral
A02BC02 [21600097]
6.3e-01
1.1e+00
1.9e+00
—
1.3e+00
1.0e+00
8.5e-01
cases:11.18%
controls:6.29%
cases:10.22%
controls:3.67%
cases:3.19%
controls:0.48%
—
—
cases:2.91%
controls:0.83%
cases:9.67%
controls:3.74%
cases:21.91%
controls:10.71%
35
197
278
2933
32
115
281
3015
10
15
303
3115
—
9
26
300
3104
29
116
271
2988
62
320
221
2667
prednisone; oral
H02AB07 [21602735]
1.6e+00
1.4e+00
—
—
—
1.8e+00
9.9e-01
cases:7.35%
controls:1.53%
cases:3.19%
controls:0.80%
—
—
—
—
—
—
cases:4.67%
controls:0.77%
cases:3.89%
controls:1.47%
23
48
290
3082
10
25
303
3105
—
—
—
14
24
286
3080
11
44
272
2943
prednisone
A07EA03 [21600655]
1.6e+00
1.4e+00
—
—
—
1.8e+00
9.9e-01
cases:7.35%
controls:1.53%
cases:3.19%
controls:0.80%
—
—
—
—
—
—
cases:4.67%
controls:0.77%
cases:3.89%
controls:1.47%
23
48
290
3082
10
25
303
3105
—
—
—
14
24
286
3080
11
44
272
2943
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.2e-01
7.8e-01
1.9e+00
—
2.3e+00
1.5e+00
9.9e-01
cases:2.88%
controls:1.73%
cases:3.83%
controls:1.79%
cases:1.92%
controls:0.29%
—
—
cases:2.59%
controls:0.26%
cases:6.67%
controls:1.64%
cases:15.90%
controls:6.56%
9
54
304
3076
12
56
301
3074
6
9
307
3121
—
8
8
301
3122
20
51
280
3053
45
196
238
2791
Case Management Agency
251B00000X [38004193]
5.1e-01
3.2e-01
8.2e-01
2.9e+00
2.5e-01
4.6e-01
3.0e-01
cases:32.91%
controls:22.72%
cases:22.04%
controls:17.03%
cases:10.86%
controls:5.11%
cases:3.83%
controls:0.22%
cases:7.12%
controls:5.62%
cases:27.67%
controls:19.39%
cases:48.76%
controls:41.28%
103
711
210
2419
69
533
244
2597
34
160
279
2970
12
7
301
3123
22
176
287
2954
83
602
217
2502
138
1233
145
1754
clonazepam; oral, parenteral
N03AE01 [21604415]
2.2e+00
2.3e+00
—
—
—
1.8e+00
1.3e+00
cases:4.47%
controls:0.51%
cases:2.56%
controls:0.26%
—
—
—
—
—
—
cases:1.67%
controls:0.29%
cases:2.83%
controls:0.77%
14
16
299
3114
8
8
305
3122
—
—
—
5
9
295
3095
8
23
275
2964
Nephrology
39 [38004479]
2.2e+00
—
1.0e+50
—
—
1.9e+00
2.2e+00
cases:2.88%
controls:0.32%
—
—
cases:1.60%
controls:0.00%
—
—
—
—
cases:1.67%
controls:0.26%
cases:3.53%
controls:0.40%
9
10
304
3120
—
5
0
308
3130
—
—
5
8
295
3096
10
12
273
2975
allopurinol; oral, parenteral
M04AA01 [21604131]
1.5e+00
1.4e+00
—
—
—
1.5e+00
9.4e-01
cases:5.75%
controls:1.41%
cases:4.47%
controls:1.09%
—
—
—
—
—
—
cases:4.33%
controls:1.00%
cases:4.59%
controls:1.84%
18
44
295
3086
14
34
299
3096
—
—
—
13
31
287
3073
13
55
270
2932
One hour or less
ZXE00 [2001311394]
9.8e-01
1.2e+00
—
—
—
1.3e+00
8.2e-01
cases:10.54%
controls:4.22%
cases:4.47%
controls:1.34%
—
—
—
—
—
—
cases:4.67%
controls:1.26%
cases:12.01%
controls:5.69%
33
132
280
2998
14
42
299
3088
—
—
—
14
39
286
3065
34
170
249
2817
Infection following a procedure, not elsewhere classified
T81.4 [45575538]
1.6e+00
2.3e+00
—
—
—
—
2.0e+00
cases:2.24%
controls:0.45%
cases:1.92%
controls:0.19%
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.50%
7
14
306
3116
6
6
307
3124
—
—
—
—
10
15
273
2972
CBC panel - Blood by Automated count
58410-2 [40761511]
8.3e-02
2.1e-01
2.2e+00
—
2.1e+00
5.1e-01
3.5e-01
cases:4.15%
controls:3.83%
cases:4.47%
controls:3.64%
cases:4.15%
controls:0.48%
—
—
cases:4.53%
controls:0.58%
cases:6.33%
controls:3.90%
cases:17.67%
controls:13.19%
13
120
300
3010
14
114
299
3016
13
15
300
3115
—
14
18
295
3112
19
121
281
2983
50
394
233
2593
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
4.0e-01
5.8e-01
2.1e+00
—
2.1e+00
7.7e-01
2.1e-01
cases:2.88%
controls:1.95%
cases:4.15%
controls:2.36%
cases:3.19%
controls:0.42%
—
—
cases:2.59%
controls:0.32%
cases:5.33%
controls:2.55%
cases:10.25%
controls:8.44%
9
61
304
3069
13
74
300
3056
10
13
303
3117
—
8
10
301
3120
16
79
284
3025
29
252
254
2735
mesalazine; oral, rectal
A07EC02 [21600664]
—
—
—
—
1.0e+50
—
4.1e+00
—
—
—
—
—
—
—
—
cases:4.21%
controls:0.00%
—
—
cases:10.95%
controls:0.20%
—
—
—
—
13
0
296
3130
—
31
6
252
2981
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.1e-01
4.7e-01
2.0e+00
—
2.1e+00
5.5e-01
5.0e-01
cases:4.47%
controls:3.67%
cases:6.07%
controls:3.87%
cases:3.19%
controls:0.45%
—
—
cases:4.53%
controls:0.58%
cases:7.00%
controls:4.16%
cases:19.43%
controls:12.79%
14
115
299
3015
19
121
294
3009
10
14
303
3116
—
14
18
295
3112
21
129
279
2975
55
382
228
2605
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
2.0e-01
4.7e-01
2.0e+00
—
2.1e+00
5.4e-01
4.8e-01
cases:4.47%
controls:3.71%
cases:6.07%
controls:3.90%
cases:3.51%
controls:0.51%
—
—
cases:4.85%
controls:0.61%
cases:7.00%
controls:4.19%
cases:19.43%
controls:12.96%
14
116
299
3014
19
122
294
3008
11
16
302
3114
—
15
19
294
3111
21
130
279
2974
55
387
228
2600
Scheduled procedure
ZXD10 [2001311387]
9.1e-01
1.1e+00
—
—
-1.0e+50
1.2e+00
8.4e-01
cases:9.90%
controls:4.22%
cases:5.43%
controls:1.82%
—
—
—
—
cases:0.00%
controls:0.16%
cases:4.67%
controls:1.51%
cases:11.31%
controls:5.22%
31
132
282
2998
17
57
296
3073
—
—
0
5
309
3125
14
47
286
3057
32
156
251
2831
furosemide; oral, parenteral
C03CA01 [21601518]
1.2e+00
1.1e+00
1.1e+00
—
8.1e-01
8.5e-01
8.4e-01
cases:11.50%
controls:3.77%
cases:8.95%
controls:3.07%
cases:2.24%
controls:0.77%
—
—
cases:2.27%
controls:1.02%
cases:8.33%
controls:3.74%
cases:13.78%
controls:6.46%
36
118
277
3012
28
96
285
3034
7
24
306
3106
—
7
32
302
3098
25
116
275
2988
39
193
244
2794
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
2.3e+00
—
—
—
—
—
1.6e+00
cases:1.92%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:2.83%
controls:0.57%
6
6
307
3124
—
—
—
—
—
8
17
275
2970
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
8.6e-02
3.8e-01
1.9e+00
—
1.9e+00
5.9e-01
4.1e-01
cases:4.47%
controls:4.12%
cases:6.71%
controls:4.70%
cases:4.47%
controls:0.67%
—
—
cases:4.85%
controls:0.73%
cases:8.00%
controls:4.61%
cases:19.79%
controls:14.13%
14
129
299
3001
21
147
292
2983
14
21
299
3109
—
15
23
294
3107
24
143
276
2961
56
422
227
2565
temazepam; oral
N05CD07 [21604642]
1.2e+00
1.4e+00
—
—
—
1.2e+00
8.5e-01
cases:8.95%
controls:2.84%
cases:7.03%
controls:1.82%
—
—
—
—
—
—
cases:6.33%
controls:1.93%
cases:7.07%
controls:3.15%
28
89
285
3041
22
57
291
3073
—
—
—
19
60
281
3044
20
94
263
2893
Bacterial infection, unspecified
A49.9 [45590816]
2.5e+00
—
—
—
—
—
1.3e+00
cases:2.24%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
cases:4.24%
controls:1.17%
7
6
306
3124
—
—
—
—
—
12
35
271
2952
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.9e-01
2.2e-01
1.7e+00
—
2.0e+00
6.8e-01
5.2e-01
cases:3.19%
controls:2.65%
cases:3.83%
controls:3.10%
cases:3.19%
controls:0.58%
—
—
cases:3.24%
controls:0.45%
cases:6.00%
controls:3.13%
cases:14.49%
controls:9.14%
10
83
303
3047
12
97
301
3033
10
18
303
3112
—
10
14
299
3116
18
97
282
3007
41
273
242
2714
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
3.0e-01
2.1e-01
1.8e+00
—
1.9e+00
6.9e-01
3.7e-01
cases:4.79%
controls:3.61%
cases:5.11%
controls:4.19%
cases:3.83%
controls:0.67%
—
—
cases:4.85%
controls:0.73%
cases:7.67%
controls:3.99%
cases:16.96%
controls:12.35%
15
113
298
3017
16
131
297
2999
12
21
301
3109
—
15
23
294
3107
23
124
277
2980
48
369
235
2618
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1.1e+00
—
—
—
—
2.4e+00
1.3e+00
cases:1.60%
controls:0.51%
—
—
—
—
—
—
—
—
cases:2.00%
controls:0.19%
cases:7.42%
controls:2.04%
5
16
308
3114
—
—
—
—
6
6
294
3098
21
61
262
2926
Essential (primary) hypertension
I10 [45591453]
6.9e-01
7.2e-01
1.4e+00
—
2.0e+00
9.6e-01
3.1e-01
cases:13.10%
controls:7.06%
cases:7.03%
controls:3.55%
cases:2.88%
controls:0.73%
—
—
cases:3.56%
controls:0.48%
cases:8.67%
controls:3.51%
cases:15.90%
controls:12.22%
41
221
272
2909
22
111
291
3019
9
23
304
3107
—
11
15
298
3115
26
109
274
2995
45
365
238
2622
clindamycin; oral, parenteral
J01FF01 [21602985]
1.3e+00
2.4e+00
—
—
—
1.0e+00
8.0e-01
cases:7.03%
controls:2.11%
cases:7.03%
controls:0.67%
—
—
—
—
—
—
cases:2.67%
controls:0.97%
cases:7.42%
controls:3.48%
22
66
291
3064
22
21
291
3109
—
—
—
8
30
292
3074
21
104
262
2883
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
1.1e+00
9.3e-01
—
—
—
1.6e+00
9.6e-01
cases:4.47%
controls:1.57%
cases:1.92%
controls:0.77%
—
—
—
—
—
—
cases:2.67%
controls:0.55%
cases:6.36%
controls:2.54%
14
49
299
3081
6
24
307
3106
—
—
—
8
17
292
3087
18
76
265
2911
Orthopedic Surgery
20 [38004465]
7.3e-01
1.2e+00
1.2e+00
—
1.5e+00
1.1e+00
5.8e-01
cases:12.78%
controls:6.58%
cases:8.95%
controls:2.81%
cases:1.60%
controls:0.48%
—
—
cases:1.62%
controls:0.35%
cases:8.00%
controls:2.90%
cases:17.67%
controls:10.71%
40
206
273
2924
28
88
285
3042
5
15
308
3115
—
5
11
304
3119
24
90
276
3014
50
320
233
2667
Medical doctor
Z2221 [2001311556]
7.6e-01
1.3e+00
—
1.0e+50
—
1.3e+00
1.0e+00
cases:5.11%
controls:2.46%
cases:5.43%
controls:1.57%
—
—
cases:1.92%
controls:0.00%
—
—
cases:4.67%
controls:1.32%
cases:10.25%
controls:3.95%
16
77
297
3053
17
49
296
3081
—
6
0
307
3130
—
14
41
286
3063
29
118
254
2869
zopiclone; oral
N05CF01 [21604654]
9.4e-01
8.9e-01
8.9e-01
—
1.1e+00
8.4e-01
9.0e-01
cases:14.70%
controls:6.29%
cases:9.90%
controls:4.31%
cases:2.24%
controls:0.93%
—
—
cases:3.56%
controls:1.18%
cases:10.00%
controls:4.57%
cases:17.67%
controls:8.00%
46
197
267
2933
31
135
282
2995
7
29
306
3101
—
11
37
298
3093
30
142
270
2962
50
239
233
2748
omeprazole; oral, parenteral
A02BC01 [21600096]
1.2e+00
1.5e+00
—
—
1.1e+00
9.6e-01
8.3e-01
cases:11.82%
controls:3.77%
cases:7.35%
controls:1.79%
—
—
—
—
cases:1.62%
controls:0.54%
cases:4.67%
controls:1.84%
cases:9.89%
controls:4.59%
37
118
276
3012
23
56
290
3074
—
—
5
17
304
3113
14
57
286
3047
28
137
255
2850
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.4e-01
2.2e-01
1.7e+00
—
1.8e+00
5.7e-01
3.1e-01
cases:5.43%
controls:4.76%
cases:6.39%
controls:5.18%
cases:4.79%
controls:0.89%
—
—
cases:5.50%
controls:0.96%
cases:9.00%
controls:5.32%
cases:20.49%
controls:15.90%
17
149
296
2981
20
162
293
2968
15
28
298
3102
—
17
30
292
3100
27
165
273
2939
58
475
225
2512
Platelets [#/volume] in Blood
26515-7 [3007461]
1.5e-01
2.2e-01
1.7e+00
—
1.8e+00
5.7e-01
3.1e-01
cases:5.43%
controls:4.70%
cases:6.39%
controls:5.18%
cases:4.79%
controls:0.89%
—
—
cases:5.50%
controls:0.96%
cases:9.00%
controls:5.32%
cases:20.49%
controls:15.87%
17
147
296
2983
20
162
293
2968
15
28
298
3102
—
17
30
292
3100
27
165
273
2939
58
474
225
2513
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.4e-01
2.2e-01
1.7e+00
—
1.8e+00
5.7e-01
3.1e-01
cases:5.43%
controls:4.76%
cases:6.39%
controls:5.18%
cases:4.79%
controls:0.89%
—
—
cases:5.50%
controls:0.96%
cases:9.00%
controls:5.32%
cases:20.49%
controls:15.90%
17
149
296
2981
20
162
293
2968
15
28
298
3102
—
17
30
292
3100
27
165
273
2939
58
475
225
2512
MCH [Entitic mass]
28539-5 [3035941]
1.4e-01
2.2e-01
1.7e+00
—
1.8e+00
5.7e-01
3.1e-01
cases:5.43%
controls:4.76%
cases:6.39%
controls:5.18%
cases:4.79%
controls:0.89%
—
—
cases:5.50%
controls:0.96%
cases:9.00%
controls:5.32%
cases:20.49%
controls:15.87%
17
149
296
2981
20
162
293
2968
15
28
298
3102
—
17
30
292
3100
27
165
273
2939
58
474
225
2513
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.4e-01
2.2e-01
1.7e+00
—
1.8e+00
5.7e-01
3.1e-01
cases:5.43%
controls:4.76%
cases:6.39%
controls:5.18%
cases:4.79%
controls:0.89%
—
—
cases:5.50%
controls:0.99%
cases:9.00%
controls:5.32%
cases:20.49%
controls:15.87%
17
149
296
2981
20
162
293
2968
15
28
298
3102
—
17
31
292
3099
27
165
273
2939
58
474
225
2513
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.4e-01
2.2e-01
1.7e+00
—
1.8e+00
5.7e-01
3.1e-01
cases:5.43%
controls:4.76%
cases:6.39%
controls:5.18%
cases:4.79%
controls:0.89%
—
—
cases:5.50%
controls:0.99%
cases:9.00%
controls:5.32%
cases:20.49%
controls:15.90%
17
149
296
2981
20
162
293
2968
15
28
298
3102
—
17
31
292
3099
27
165
273
2939
58
475
225
2512
amoxicillin; oral, parenteral
J01CA04 [21602823]
4.3e-01
6.5e-01
3.5e+00
—
—
2.9e-01
2.3e-01
cases:27.16%
controls:19.52%
cases:10.22%
controls:5.59%
cases:14.70%
controls:0.54%
—
—
—
—
cases:8.33%
controls:6.38%
cases:24.73%
controls:20.69%
85
611
228
2519
32
175
281
2955
46
17
267
3113
—
—
25
198
275
2906
70
618
213
2369
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.4e-01
2.2e-01
1.7e+00
—
1.8e+00
5.6e-01
3.1e-01
cases:5.43%
controls:4.76%
cases:6.39%
controls:5.18%
cases:4.79%
controls:0.93%
—
—
cases:5.50%
controls:0.99%
cases:9.00%
controls:5.35%
cases:20.49%
controls:15.94%
17
149
296
2981
20
162
293
2968
15
29
298
3101
—
17
31
292
3099
27
166
273
2938
58
476
225
2511
salbutamol; inhalant
R03AC02 [21603256]
9.6e-01
8.3e-01
—
—
1.1e+00
8.8e-01
7.7e-01
cases:15.65%
controls:6.65%
cases:8.63%
controls:3.96%
—
—
—
—
cases:1.94%
controls:0.67%
cases:9.67%
controls:4.25%
cases:19.79%
controls:10.24%
49
208
264
2922
27
124
286
3006
—
—
6
21
303
3109
29
132
271
2972
56
306
227
2681
Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]
1.1e+00
2.1e+00
—
—
—
—
1.3e+00
cases:2.56%
controls:0.86%
cases:2.24%
controls:0.29%
—
—
—
—
—
—
—
—
cases:3.89%
controls:1.07%
8
27
305
3103
7
9
306
3121
—
—
—
—
11
32
272
2955
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
5.7e-01
1.0e+00
7.1e-01
—
8.1e-01
9.4e-01
8.3e-01
cases:18.21%
controls:11.18%
cases:15.02%
controls:5.97%
cases:2.88%
controls:1.44%
—
—
cases:2.27%
controls:1.02%
cases:17.00%
controls:7.41%
cases:40.64%
controls:22.90%
57
350
256
2780
47
187
266
2943
9
45
304
3085
—
7
32
302
3098
51
230
249
2874
115
684
168
2303
hydroxychloroquine; oral
P01BA02 [21604889]
1.8e+00
—
—
—
—
1.2e+00
1.5e+00
cases:3.19%
controls:0.54%
—
—
—
—
—
—
—
—
cases:1.67%
controls:0.48%
cases:3.89%
controls:0.87%
10
17
303
3113
—
—
—
—
5
15
295
3089
11
26
272
2961
Pain localized to upper abdomen
R10.1 [45568111]
1.7e+00
—
—
—
—
—
1.5e+00
cases:2.88%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:3.18%
controls:0.70%
9
17
304
3113
—
—
—
—
—
9
21
274
2966
Pneumonia, unspecified
J18.9 [45601123]
1.1e+00
2.1e+00
—
—
—
1.2e+00
6.5e-01
cases:4.15%
controls:1.37%
cases:4.15%
controls:0.54%
—
—
—
—
—
—
cases:2.67%
controls:0.84%
cases:6.01%
controls:3.21%
13
43
300
3087
13
17
300
3113
—
—
—
8
26
292
3078
17
96
266
2891
Headache
R51.80 [2000503603]
1.6e+00
—
—
—
—
—
1.6e+00
cases:3.51%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
cases:5.65%
controls:1.21%
11
23
302
3107
—
—
—
—
—
16
36
267
2951
pravastatin; oral
C10AA03 [21601858]
6.2e-01
1.3e+00
—
—
—
1.6e+00
1.6e+00
cases:1.60%
controls:0.86%
cases:1.60%
controls:0.45%
—
—
—
—
—
—
cases:3.00%
controls:0.61%
cases:4.95%
controls:1.07%
5
27
308
3103
5
14
308
3116
—
—
—
9
19
291
3085
14
32
269
2955
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
9.4e-01
1.0e+00
—
—
—
1.5e+00
7.6e-01
cases:10.54%
controls:4.41%
cases:4.15%
controls:1.57%
—
—
—
—
—
—
cases:5.67%
controls:1.35%
cases:12.01%
controls:5.99%
33
138
280
2992
13
49
300
3081
—
—
—
17
42
283
3062
34
179
249
2808
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
—
—
—
1.0e+50
—
—
3.2e+00
—
—
—
—
—
—
cases:1.60%
controls:0.00%
—
—
—
—
cases:5.30%
controls:0.23%
—
—
—
5
0
308
3130
—
—
15
7
268
2980
codeine and paracetamol
N02AJ06 [1123647]
7.7e-01
1.2e+00
1.9e+00
—
—
9.6e-01
9.3e-01
cases:7.67%
controls:3.71%
cases:6.07%
controls:1.82%
cases:1.92%
controls:0.29%
—
—
—
—
cases:6.00%
controls:2.38%
cases:18.73%
controls:8.37%
24
116
289
3014
19
57
294
3073
6
9
307
3121
—
—
18
74
282
3030
53
250
230
2737
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
1.4e+00
1.3e+00
—
—
—
2.1e+00
1.0e+00
cases:2.24%
controls:0.58%
cases:1.60%
controls:0.45%
—
—
—
—
—
—
cases:3.00%
controls:0.39%
cases:7.77%
controls:3.01%
7
18
306
3112
5
14
308
3116
—
—
—
9
12
291
3092
22
90
261
2897
Urgent procedure
ZXD05 [2001311386]
5.7e-01
1.4e+00
—
—
—
1.6e+00
4.8e-01
cases:5.43%
controls:3.13%
cases:4.47%
controls:1.09%
—
—
—
—
—
—
cases:2.67%
controls:0.55%
cases:6.36%
controls:4.02%
17
98
296
3032
14
34
299
3096
—
—
—
8
17
292
3087
18
120
265
2867
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1.4e+00
1.3e+00
—
—
—
1.6e+00
1.4e+00
cases:2.56%
controls:0.67%
cases:3.19%
controls:0.86%
—
—
—
—
—
—
cases:3.33%
controls:0.71%
cases:10.60%
controls:2.85%
8
21
305
3109
10
27
303
3103
—
—
—
10
22
290
3082
30
85
253
2902
Enterocolitis due to Clostridium difficile
A04.7 [45552153]
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
3.0e+00
—
—
cases:3.19%
controls:0.00%
cases:3.51%
controls:0.00%
cases:6.07%
controls:0.00%
cases:2.91%
controls:0.00%
—
—
cases:3.18%
controls:0.17%
—
10
0
303
3130
11
0
302
3130
19
0
294
3130
9
0
300
3130
—
9
5
274
2982
combinations of corticosteroids
D07XB30 [21602188]
4.6e-01
6.1e-01
1.4e+00
—
2.2e+00
2.8e-01
7.3e-01
cases:14.70%
controls:9.81%
cases:5.11%
controls:2.84%
cases:1.60%
controls:0.38%
—
—
cases:2.59%
controls:0.29%
cases:4.33%
controls:3.32%
cases:17.31%
controls:9.14%
46
307
267
2823
16
89
297
3041
5
12
308
3118
—
8
9
301
3121
13
103
287
3001
49
273
234
2714
combinations of corticosteroids
D07AB30 [21602118]
4.6e-01
6.1e-01
1.4e+00
—
2.2e+00
2.8e-01
7.3e-01
cases:14.70%
controls:9.81%
cases:5.11%
controls:2.84%
cases:1.60%
controls:0.38%
—
—
cases:2.59%
controls:0.29%
cases:4.33%
controls:3.32%
cases:17.31%
controls:9.14%
46
307
267
2823
16
89
297
3041
5
12
308
3118
—
8
9
301
3121
13
103
287
3001
49
273
234
2714
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.0e+00
1.4e+00
—
—
—
1.6e+00
1.3e+00
cases:1.60%
controls:0.58%
cases:1.60%
controls:0.42%
—
—
—
—
—
—
cases:2.67%
controls:0.55%
cases:7.42%
controls:2.04%
5
18
308
3112
5
13
308
3117
—
—
—
8
17
292
3087
21
61
262
2926
pregabalin; oral
N02BF02 [955152]
9.6e-01
1.1e+00
—
—
1.5e+00
1.4e+00
1.6e+00
cases:3.19%
controls:1.25%
cases:2.56%
controls:0.83%
—
—
—
—
cases:1.62%
controls:0.35%
cases:3.33%
controls:0.87%
cases:12.72%
controls:2.91%
10
39
303
3091
8
26
305
3104
—
—
5
11
304
3119
10
27
290
3077
36
87
247
2900
potassium chloride; oral
A12BA01 [21600877]
1.4e+00
1.1e+00
—
—
—
1.5e+00
1.0e+00
cases:3.51%
controls:0.86%
cases:1.92%
controls:0.67%
—
—
—
—
—
—
cases:3.00%
controls:0.68%
cases:3.53%
controls:1.27%
11
27
302
3103
6
21
307
3109
—
—
—
9
21
291
3083
10
38
273
2949
Other specified special examinations
Z01.8 [45581003]
1.3e+00
1.6e+00
—
—
—
1.5e+00
4.5e-01
cases:3.83%
controls:1.02%
cases:2.88%
controls:0.61%
—
—
—
—
—
—
cases:2.33%
controls:0.55%
cases:3.18%
controls:2.04%
12
32
301
3098
9
19
304
3111
—
—
—
7
17
293
3087
9
61
274
2926
phenoxymethylpenicillin; oral
J01CE02 [21602842]
3.1e-01
3.2e-01
2.9e+00
—
-1.0e+50
5.7e-01
1.9e-01
cases:14.38%
controls:10.99%
cases:4.47%
controls:3.29%
cases:5.11%
controls:0.29%
—
—
cases:0.00%
controls:0.42%
cases:5.67%
controls:3.29%
cases:14.49%
controls:12.25%
45
344
268
2786
14
103
299
3027
16
9
297
3121
—
0
13
309
3117
17
102
283
3002
41
366
242
2621
benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]
3.1e-01
3.2e-01
2.9e+00
—
-1.0e+50
5.7e-01
1.9e-01
cases:14.38%
controls:10.99%
cases:4.47%
controls:3.29%
cases:5.11%
controls:0.29%
—
—
cases:0.00%
controls:0.42%
cases:5.67%
controls:3.29%
cases:14.49%
controls:12.25%
45
344
268
2786
14
103
299
3027
16
9
297
3121
—
0
13
309
3117
17
102
283
3002
41
366
242
2621
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
9.7e-01
8.5e-01
—
—
—
1.9e+00
1.0e+00
cases:2.24%
controls:0.86%
cases:1.92%
controls:0.83%
—
—
—
—
—
—
cases:3.00%
controls:0.48%
cases:9.54%
controls:3.58%
7
27
306
3103
6
26
307
3104
—
—
—
9
15
291
3089
27
107
256
2880
Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]
—
—
—
—
—
—
2.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.83%
controls:0.17%
—
—
—
—
—
—
8
5
275
2982
Basophils [#/volume] in Blood
26444-0 [3006315]
8.7e-01
1.2e+00
—
—
—
1.6e+00
1.2e+00
cases:2.56%
controls:1.09%
cases:2.88%
controls:0.86%
—
—
—
—
—
—
cases:4.33%
controls:0.87%
cases:10.95%
controls:3.58%
8
34
305
3096
9
27
304
3103
—
—
—
13
27
287
3077
31
107
252
2880
Monocytes [#/volume] in Blood
26484-6 [3001604]
9.3e-01
1.2e+00
—
—
—
1.6e+00
1.2e+00
cases:2.56%
controls:1.02%
cases:2.88%
controls:0.86%
—
—
—
—
—
—
cases:4.33%
controls:0.87%
cases:10.95%
controls:3.58%
8
32
305
3098
9
27
304
3103
—
—
—
13
27
287
3077
31
107
252
2880
Eosinophils [#/volume] in Blood
26449-9 [3013115]
8.1e-01
1.2e+00
—
—
—
1.7e+00
1.1e+00
cases:2.56%
controls:1.15%
cases:2.88%
controls:0.89%
—
—
—
—
—
—
cases:4.33%
controls:0.84%
cases:10.95%
controls:3.82%
8
36
305
3094
9
28
304
3102
—
—
—
13
26
287
3078
31
114
252
2873
Normoblasts [#/volume] in Blood
715-3 [3021589]
9.3e-01
9.7e-01
—
—
—
1.8e+00
9.8e-01
cases:1.60%
controls:0.64%
cases:2.24%
controls:0.86%
—
—
—
—
—
—
cases:3.67%
controls:0.61%
cases:6.36%
controls:2.48%
5
20
308
3110
7
27
306
3103
—
—
—
11
19
289
3085
18
74
265
2913
Basophils/Leukocytes in Blood
30180-4 [3022096]
8.3e-01
1.2e+00
—
—
—
1.6e+00
1.2e+00
cases:2.24%
controls:0.99%
cases:2.56%
controls:0.77%
—
—
—
—
—
—
cases:4.00%
controls:0.81%
cases:10.25%
controls:3.45%
7
31
306
3099
8
24
305
3106
—
—
—
12
25
288
3079
29
103
254
2884
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
7.9e-01
1.2e+00
—
—
—
1.6e+00
1.2e+00
cases:2.24%
controls:1.02%
cases:2.56%
controls:0.80%
—
—
—
—
—
—
cases:4.00%
controls:0.81%
cases:10.25%
controls:3.48%
7
32
306
3098
8
25
305
3105
—
—
—
12
25
288
3079
29
104
254
2883
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
6.8e-01
1.0e+00
1.9e+00
—
1.6e+00
1.7e+00
1.1e+00
cases:2.56%
controls:1.31%
cases:3.51%
controls:1.28%
cases:1.92%
controls:0.29%
—
—
cases:1.62%
controls:0.32%
cases:5.00%
controls:1.00%
cases:11.31%
controls:4.02%
8
41
305
3089
11
40
302
3090
6
9
307
3121
—
5
10
304
3120
15
31
285
3073
32
120
251
2867
Monocytes/Leukocytes in Blood
26485-3 [3019069]
7.9e-01
1.2e+00
—
—
—
1.6e+00
1.2e+00
cases:2.24%
controls:1.02%
cases:2.56%
controls:0.80%
—
—
—
—
—
—
cases:4.00%
controls:0.84%
cases:10.25%
controls:3.48%
7
32
306
3098
8
25
305
3105
—
—
—
12
26
288
3078
29
104
254
2883
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
7.8e-01
1.1e+00
—
—
—
1.6e+00
1.2e+00
cases:2.56%
controls:1.18%
cases:2.88%
controls:0.96%
—
—
—
—
—
—
cases:4.33%
controls:0.93%
cases:11.31%
controls:3.82%
8
37
305
3093
9
30
304
3100
—
—
—
13
29
287
3075
32
114
251
2873
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.65%
controls:0.40%
—
—
—
—
—
—
16
12
267
2975
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
8.6e-01
1.1e+00
—
—
—
1.5e+00
1.1e+00
cases:2.24%
controls:0.96%
cases:2.56%
controls:0.86%
—
—
—
—
—
—
cases:4.00%
controls:0.90%
cases:10.60%
controls:3.65%
7
30
306
3100
8
27
305
3103
—
—
—
12
28
288
3076
30
109
253
2878
Asthma, unspecified
J45.9 [45562456]
1.1e+00
1.6e+00
—
—
—
1.6e+00
1.1e+00
cases:3.83%
controls:1.34%
cases:2.24%
controls:0.45%
—
—
—
—
—
—
cases:2.67%
controls:0.55%
cases:6.01%
controls:2.18%
12
42
301
3088
7
14
306
3116
—
—
—
8
17
292
3087
17
65
266
2922
Physiotherapy
R4110 [2001310233]
1.4e+00
1.0e+00
—
—
—
1.2e+00
1.2e+00
cases:3.83%
controls:0.96%
cases:1.92%
controls:0.70%
—
—
—
—
—
—
cases:2.00%
controls:0.61%
cases:8.48%
controls:2.61%
12
30
301
3100
6
22
307
3108
—
—
—
6
19
294
3085
24
78
259
2909
roxithromycin; oral
J01FA06 [21602974]
7.4e-01
1.0e+00
—
—
-1.0e+50
9.0e-01
8.5e-01
cases:14.06%
controls:7.25%
cases:4.47%
controls:1.63%
—
—
—
—
cases:0.00%
controls:0.19%
cases:4.33%
controls:1.80%
cases:11.66%
controls:5.32%
44
227
269
2903
14
51
299
3079
—
—
0
6
309
3124
13
56
287
3048
33
159
250
2828
Bacteria identified in Stool by Culture
625-4 [3025941]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.27%
—
—
—
—
—
—
10
8
273
2979
azithromycin; oral, parenteral
J01FA10 [21602978]
5.6e-01
5.6e-01
—
—
—
1.3e+00
7.9e-01
cases:18.53%
controls:11.53%
cases:5.11%
controls:2.97%
—
—
—
—
—
—
cases:7.67%
controls:2.32%
cases:17.31%
controls:8.70%
58
361
255
2769
16
93
297
3037
—
—
—
23
72
277
3032
49
260
234
2727
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
7.9e-01
9.7e-01
—
—
—
1.6e+00
1.0e+00
cases:2.24%
controls:1.02%
cases:2.24%
controls:0.86%
—
—
—
—
—
—
cases:4.00%
controls:0.87%
cases:9.54%
controls:3.62%
7
32
306
3098
7
27
306
3103
—
—
—
12
27
288
3077
27
108
256
2879
Bacterial pneumonia, unspecified
J15.9 [45557621]
—
2.6e+00
1.0e+50
—
—
—
—
—
—
cases:2.88%
controls:0.22%
cases:2.24%
controls:0.00%
—
—
—
—
—
—
—
—
—
9
7
304
3123
7
0
306
3130
—
—
—
—
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
1.6e+00
2.5e+00
—
—
—
—
6.6e-01
cases:1.92%
controls:0.38%
cases:1.92%
controls:0.16%
—
—
—
—
—
—
—
—
cases:2.12%
controls:1.10%
6
12
307
3118
6
5
307
3125
—
—
—
—
6
33
277
2954
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
2.5e+00
—
—
—
—
2.2e+00
1.2e+00
cases:1.92%
controls:0.16%
—
—
—
—
—
—
—
—
cases:1.67%
controls:0.19%
cases:1.77%
controls:0.54%
6
5
307
3125
—
—
—
—
5
6
295
3098
5
16
278
2971
zolpidem; oral
N05CF02 [21604655]
1.3e+00
1.3e+00
-1.0e+50
—
—
1.4e+00
1.2e+00
cases:3.83%
controls:1.12%
cases:2.88%
controls:0.80%
cases:0.00%
controls:0.26%
—
—
—
—
cases:3.00%
controls:0.77%
cases:6.36%
controls:2.04%
12
35
301
3095
9
25
304
3105
0
8
313
3122
—
—
9
24
291
3080
18
61
265
2926
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.33%
—
—
—
—
—
—
10
10
273
2977
Ileoscopy through colon
UJF30 [2001305028]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.18%
controls:0.30%
—
—
—
—
—
—
9
9
274
2978
Ova and parasites identified in Stool by Light microscopy
10704-5 [3003327]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.77%
controls:0.17%
—
—
—
—
—
—
5
5
278
2982
Fever, unspecified
R50.9 [45582716]
1.3e+00
—
—
—
—
2.4e+00
1.1e+00
cases:2.56%
controls:0.70%
—
—
—
—
—
—
—
—
cases:2.67%
controls:0.26%
cases:2.47%
controls:0.84%
8
22
305
3108
—
—
—
—
8
8
292
3096
7
25
276
2962
Rehabilitation Hospital
283X00000X [38004285]
2.3e+00
—
—
—
—
—
—
cases:2.56%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
—
—
8
8
305
3122
—
—
—
—
—
—
Emergency Medicine
93 [38004510]
7.3e-01
1.1e+00
2.3e+00
1.0e+50
—
1.2e+00
4.0e-01
cases:2.56%
controls:1.25%
cases:2.88%
controls:0.96%
cases:2.24%
controls:0.22%
cases:3.19%
controls:0.00%
—
—
cases:3.67%
controls:1.13%
cases:7.77%
controls:5.36%
8
39
305
3091
9
30
304
3100
7
7
306
3123
10
0
303
3130
—
11
35
289
3069
22
160
261
2827
pseudoephedrine, combinations; oral
R01BA52 [21603213]
5.7e-01
6.9e-01
2.3e+00
—
—
3.0e-01
5.2e-01
cases:14.70%
controls:8.91%
cases:4.79%
controls:2.46%
cases:2.24%
controls:0.22%
—
—
—
—
cases:3.33%
controls:2.48%
cases:10.25%
controls:6.33%
46
279
267
2851
15
77
298
3053
7
7
306
3123
—
—
10
77
290
3027
29
189
254
2798
Atrial fibrillation and flutter
I48 [45596206]
1.1e+00
1.3e+00
—
1.0e+50
—
9.1e-01
5.1e-01
cases:5.75%
controls:2.08%
cases:5.43%
controls:1.60%
—
—
cases:1.60%
controls:0.00%
—
—
cases:3.67%
controls:1.51%
cases:6.71%
controls:4.15%
18
65
295
3065
17
50
296
3080
—
5
0
308
3130
—
11
47
289
3057
19
124
264
2863
Gastro-oesophageal reflux disease without oesophagitis
K21.9 [45538509]
2.3e+00
—
—
—
—
—
—
cases:1.92%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
307
3124
—
—
—
—
—
—
Colonoscopy Study observation
28023-0 [3022145]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.24%
controls:0.44%
—
—
—
—
—
—
12
13
271
2974
Laboratory Visit
OMOP4822461 [32036]
9.3e-02
2.1e-01
1.2e+00
—
1.1e+00
3.1e-01
2.6e-01
cases:6.07%
controls:5.56%
cases:7.67%
controls:6.29%
cases:6.39%
controls:1.98%
—
—
cases:5.83%
controls:2.08%
cases:9.33%
controls:6.99%
cases:21.55%
controls:17.54%
19
174
294
2956
24
197
289
2933
20
62
293
3068
—
18
65
291
3065
28
217
272
2887
61
524
222
2463
Congestive heart failure
I50.0 [45567179]
1.5e+00
—
—
—
—
2.3e+00
—
cases:1.92%
controls:0.45%
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.35%
—
—
6
14
307
3116
—
—
—
—
10
11
290
3093
—
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
—
-1.0e+50
—
—
—
—
2.3e+00
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
cases:2.83%
controls:0.30%
—
0
5
313
3125
—
—
—
—
8
9
275
2978
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
2.2e+00
—
—
—
—
—
—
cases:3.51%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
11
12
302
3118
—
—
—
—
—
—
Functional dyspepsia
K30 [45591584]
2.2e+00
—
—
—
—
—
1.1e+00
cases:2.24%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
cases:1.77%
controls:0.60%
7
8
306
3122
—
—
—
—
—
5
18
278
2969
Shoulder X-ray examination without contrast
NB1AA [2001307225]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.18%
controls:0.37%
—
—
—
—
—
—
9
11
274
2976
Physical Medicine And Rehabilitation
25 [38004468]
1.2e+00
9.4e-01
-1.0e+50
—
—
4.4e-01
9.3e-01
cases:9.90%
controls:3.07%
cases:3.19%
controls:1.28%
cases:0.00%
controls:0.16%
—
—
—
—
cases:2.67%
controls:1.74%
cases:10.60%
controls:4.49%
31
96
282
3034
10
40
303
3090
0
5
313
3125
—
—
8
54
292
3050
30
134
253
2853
dexrabeprazole
A02BC07 [45893509]
2.2e+00
—
—
—
—
—
—
cases:1.92%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
307
3123
—
—
—
—
—
—
Arthrocentesis, unspecified region, unspecified region
TNX10 [2001308560]
2.2e+00
—
—
—
—
—
1.4e+00
cases:1.92%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
cases:2.12%
controls:0.54%
6
7
307
3123
—
—
—
—
—
6
16
277
2971
rabeprazole; oral
A02BC04 [21600099]
2.2e+00
—
—
—
—
—
—
cases:1.92%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
—
—
6
7
307
3123
—
—
—
—
—
—
mirtazapine; oral
N06AX11 [21604740]
1.0e+00
1.0e+00
—
—
—
1.1e+00
5.1e-01
cases:5.75%
controls:2.14%
cases:4.15%
controls:1.57%
—
—
—
—
—
—
cases:4.67%
controls:1.55%
cases:8.48%
controls:5.26%
18
67
295
3063
13
49
300
3081
—
—
—
14
48
286
3056
24
157
259
2830
Iron deficiency anaemia, unspecified
D50.9 [45605373]
—
-1.0e+50
—
—
—
—
2.1e+00
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.30%
—
0
5
313
3125
—
—
—
—
7
9
276
2978
doxycycline; oral, parenteral
J01AA02 [21602800]
5.4e-01
7.0e-01
1.4e+00
—
1.1e+00
2.4e-01
8.8e-01
cases:29.71%
controls:19.74%
cases:10.22%
controls:5.37%
cases:2.56%
controls:0.67%
—
—
cases:1.94%
controls:0.67%
cases:7.67%
controls:6.12%
cases:33.22%
controls:17.11%
93
618
220
2512
32
168
281
2962
8
21
305
3109
—
6
21
303
3109
23
190
277
2914
94
511
189
2476
duloxetine; oral
N06AX21 [21604749]
2.1e+00
—
—
—
—
—
1.3e+00
cases:2.56%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:3.53%
controls:1.00%
8
10
305
3120
—
—
—
—
—
10
30
273
2957
Swelling
A08 [2002000149]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.12%
controls:0.27%
—
—
—
—
—
—
6
8
277
2979
Postmenopausal atrophic vaginitis
N95.2 [45582430]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.12%
controls:0.27%
—
—
—
—
—
—
6
8
277
2979
saccharomyces boulardii; oral
A07FA02 [21600670]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.12%
controls:0.27%
—
—
—
—
—
—
6
8
277
2979
Examination and observation for other specified reasons
Z04.8 [45552063]
2.0e+00
2.1e+00
—
—
—
—
—
cases:2.88%
controls:0.38%
cases:1.60%
controls:0.19%
—
—
—
—
—
—
—
—
—
—
9
12
304
3118
5
6
308
3124
—
—
—
—
—
Chest pain, unspecified
R07.4 [45558450]
1.0e+00
—
—
—
—
—
1.0e+00
cases:5.11%
controls:1.95%
—
—
—
—
—
—
—
—
—
—
cases:6.71%
controls:2.48%
16
61
297
3069
—
—
—
—
—
19
74
264
2913
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y83 [45552036]
2.0e+00
—
—
—
—
—
1.4e+00
cases:1.92%
controls:0.26%
—
—
—
—
—
—
—
—
—
—
cases:1.77%
controls:0.44%
6
8
307
3122
—
—
—
—
—
5
13
278
2974
levomepromazine; oral, parenteral
N05AA02 [21604493]
1.8e+00
2.0e+00
—
—
—
—
1.5e+00
cases:1.92%
controls:0.32%
cases:1.92%
controls:0.26%
—
—
—
—
—
—
—
—
cases:1.77%
controls:0.40%
6
10
307
3120
6
8
307
3122
—
—
—
—
5
12
278
2975
Dorsalgia
M54 [45553203]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.18%
controls:0.44%
—
—
—
—
—
—
9
13
274
2974
nitrofurantoin; oral
J01XE01 [21603058]
7.6e-01
—
—
—
—
2.0e+00
4.4e-01
cases:2.24%
controls:1.05%
—
—
—
—
—
—
—
—
cases:2.33%
controls:0.32%
cases:2.83%
controls:1.84%
7
33
306
3097
—
—
—
—
7
10
293
3094
8
55
275
2932
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.37%
—
—
—
—
—
—
7
11
276
2976
celecoxib; oral
M01AH01 [21603992]
7.3e-01
1.9e+00
—
—
—
—
8.5e-01
cases:4.15%
controls:2.04%
cases:2.56%
controls:0.38%
—
—
—
—
—
—
—
—
cases:5.30%
controls:2.34%
13
64
300
3066
8
12
305
3118
—
—
—
—
15
70
268
2917
celecoxib
L01XX33 [21603805]
7.3e-01
1.9e+00
—
—
—
—
8.5e-01
cases:4.15%
controls:2.04%
cases:2.56%
controls:0.38%
—
—
—
—
—
—
—
—
cases:5.30%
controls:2.34%
13
64
300
3066
8
12
305
3118
—
—
—
—
15
70
268
2917
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
1.6e+00
—
—
—
—
1.9e+00
1.0e+00
cases:1.92%
controls:0.38%
—
—
—
—
—
—
—
—
cases:2.33%
controls:0.35%
cases:4.59%
controls:1.67%
6
12
307
3118
—
—
—
—
7
11
293
3093
13
50
270
2937
Fracture of tooth, open
S02.51 [45755762]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.83%
controls:0.44%
—
—
—
—
—
—
8
13
275
2974
methylprednisolone; oral, parenteral
H02AB04 [21602732]
9.2e-01
1.9e+00
—
—
—
1.5e+00
1.0e+00
cases:5.11%
controls:2.11%
cases:2.88%
controls:0.45%
—
—
—
—
—
—
cases:2.33%
controls:0.55%
cases:4.59%
controls:1.74%
16
66
297
3064
9
14
304
3116
—
—
—
7
17
293
3087
13
52
270
2935
itraconazole; oral, parenteral
J02AC02 [21603081]
7.5e-01
1.9e+00
—
—
—
9.6e-01
8.3e-01
cases:3.83%
controls:1.85%
cases:2.88%
controls:0.45%
—
—
—
—
—
—
cases:1.67%
controls:0.64%
cases:3.18%
controls:1.41%
12
58
301
3072
9
14
304
3116
—
—
—
5
20
295
3084
9
42
274
2945
oxazepam; oral
N05BA04 [21604569]
8.9e-01
5.6e-01
—
—
9.9e-01
6.5e-01
9.8e-01
cases:7.03%
controls:3.00%
cases:3.19%
controls:1.85%
—
—
—
—
cases:1.62%
controls:0.61%
cases:3.33%
controls:1.77%
cases:10.25%
controls:4.12%
22
94
291
3036
10
58
303
3072
—
—
5
19
304
3111
10
55
290
3049
29
123
254
2864
X-ray examination of the lungs in one projection
GD1PA [2001303645]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.83%
controls:0.47%
—
—
—
—
—
—
8
14
275
2973
budesonide; inhalant
R03BA02 [21603285]
1.0e+00
7.0e-01
7.0e-01
—
—
5.6e-01
7.5e-01
cases:10.54%
controls:3.96%
cases:5.43%
controls:2.78%
cases:1.60%
controls:0.80%
—
—
—
—
cases:5.00%
controls:2.93%
cases:10.25%
controls:5.12%
33
124
280
3006
17
87
296
3043
5
25
308
3105
—
—
15
91
285
3013
29
153
254
2834
Other specified chronic obstructive pulmonary disease
J44.8 [45586673]
1.2e+00
1.8e+00
2.3e+00
—
—
1.3e+00
9.9e-01
cases:2.88%
controls:0.86%
cases:3.19%
controls:0.54%
cases:1.60%
controls:0.16%
—
—
—
—
cases:2.67%
controls:0.77%
cases:3.89%
controls:1.47%
9
27
304
3103
10
17
303
3113
5
5
308
3125
—
—
8
24
292
3080
11
44
272
2943
Bacteria identified in Isolate by Culture
43409-2 [3042936]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.60%
—
—
—
—
—
—
10
18
273
2969
hydroxocobalamin; parenteral
B03BA03 [21601123]
1.8e+00
1.8e+00
—
—
—
—
7.3e-01
cases:1.92%
controls:0.32%
cases:2.24%
controls:0.38%
—
—
—
—
—
—
—
—
cases:2.12%
controls:1.04%
6
10
307
3120
7
12
306
3118
—
—
—
—
6
31
277
2956
hydroxocobalamin
V03AB33 [21605256]
1.8e+00
1.8e+00
—
—
—
—
7.3e-01
cases:1.92%
controls:0.32%
cases:2.24%
controls:0.38%
—
—
—
—
—
—
—
—
cases:2.12%
controls:1.04%
6
10
307
3120
7
12
306
3118
—
—
—
—
6
31
277
2956
Other investigative procedure of eye
XCW99 [2001301491]
1.8e+00
—
—
—
—
—
—
cases:2.24%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
7
12
306
3118
—
—
—
—
—
—
Diaphragmatic hernia without obstruction or gangrene
K44.9 [45533596]
1.8e+00
—
—
—
—
—
—
cases:2.24%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
—
—
7
12
306
3118
—
—
—
—
—
—
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
1.8e+00
—
—
—
—
—
—
cases:2.56%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
8
14
305
3116
—
—
—
—
—
—
cetirizine; oral
R06AE07 [21603497]
2.6e-01
7.2e-01
—
—
—
1.0e+00
7.4e-01
cases:10.86%
controls:8.59%
cases:5.75%
controls:2.88%
—
—
—
—
—
—
cases:7.33%
controls:2.77%
cases:14.84%
controls:7.67%
34
269
279
2861
18
90
295
3040
—
—
—
22
86
278
3018
42
229
241
2758
Foot and toes X-ray examination
NH3AA [2001308267]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.44%
—
—
—
—
—
—
7
13
276
2974
Knee symptom/complaint
L15 [2002000639]
1.8e+00
—
—
—
—
—
3.9e-01
cases:2.88%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:1.77%
controls:1.21%
9
16
304
3114
—
—
—
—
—
5
36
278
2951
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
1.2e+00
—
—
—
—
1.7e+00
7.8e-01
cases:2.24%
controls:0.67%
—
—
—
—
—
—
—
—
cases:2.67%
controls:0.48%
cases:6.01%
controls:2.85%
7
21
306
3109
—
—
—
—
8
15
292
3089
17
85
266
2902
nystatin; oral
A07AA02 [21600604]
1.7e+00
—
—
—
—
—
9.8e-01
cases:2.56%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
cases:2.12%
controls:0.80%
8
15
305
3115
—
—
—
—
—
6
24
277
2963
Tension-type headache
G44.2 [45581495]
1.7e+00
—
—
—
—
—
6.1e-01
cases:2.88%
controls:0.54%
—
—
—
—
—
—
—
—
—
—
cases:1.77%
controls:0.97%
9
17
304
3113
—
—
—
—
—
5
29
278
2958
Intravenous
ZX120 [2001311495]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.18%
controls:0.60%
—
—
—
—
—
—
9
18
274
2969
tiotropium bromide; inhalant
R03BB04 [21603296]
1.3e+00
1.7e+00
—
—
—
1.1e+00
8.5e-01
cases:2.56%
controls:0.70%
cases:3.19%
controls:0.61%
—
—
—
—
—
—
cases:2.33%
controls:0.77%
cases:3.53%
controls:1.54%
8
22
305
3108
10
19
303
3111
—
—
—
7
24
293
3080
10
46
273
2941
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
1.0e+00
1.7e+00
—
—
—
—
6.5e-01
cases:4.47%
controls:1.69%
cases:3.19%
controls:0.61%
—
—
—
—
—
—
—
—
cases:7.42%
controls:4.02%
14
53
299
3077
10
19
303
3111
—
—
—
—
21
120
262
2867
Anxiety disorder, unspecified
F41.9 [45542849]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.83%
controls:0.54%
—
—
—
—
—
—
8
16
275
2971
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
1.1e+00
1.1e+00
—
—
—
1.7e+00
4.8e-01
cases:2.88%
controls:0.96%
cases:2.24%
controls:0.73%
—
—
—
—
—
—
cases:3.67%
controls:0.71%
cases:6.71%
controls:4.25%
9
30
304
3100
7
23
306
3107
—
—
—
11
22
289
3082
19
127
264
2860
Acute tubulo-interstitial nephritis
N10 [45543856]
1.6e+00
—
—
—
—
—
1.1e+00
cases:3.51%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
cases:2.47%
controls:0.87%
11
22
302
3108
—
—
—
—
—
7
26
276
2961
ebastine; oral
R06AX22 [21603521]
6.1e-01
1.6e+00
—
—
—
8.1e-01
8.8e-01
cases:3.51%
controls:1.95%
cases:3.19%
controls:0.64%
—
—
—
—
—
—
cases:2.00%
controls:0.90%
cases:6.36%
controls:2.75%
11
61
302
3069
10
20
303
3110
—
—
—
6
28
294
3076
18
82
265
2905
Abdominal ultrasound examination
JN3AE [2001305555]
—
—
—
—
—
-1.0e+50
1.6e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
cases:4.24%
controls:0.87%
—
—
—
—
—
0
5
300
3099
12
26
271
2961
Infiltration anesthesia
WX110 [2001310767]
5.1e-01
1.0e+00
—
—
-1.0e+50
3.1e-01
6.1e-01
cases:5.75%
controls:3.55%
cases:5.11%
controls:1.95%
—
—
—
—
cases:0.00%
controls:0.19%
cases:3.00%
controls:2.22%
cases:15.55%
controls:9.11%
18
111
295
3019
16
61
297
3069
—
—
0
6
309
3124
9
69
291
3035
44
272
239
2715
hydrocortisone
A07EA02 [21600654]
6.8e-01
7.8e-01
-1.0e+50
—
—
5.6e-01
9.2e-01
cases:12.46%
controls:6.71%
cases:3.83%
controls:1.79%
cases:0.00%
controls:0.35%
—
—
—
—
cases:3.33%
controls:1.93%
cases:15.55%
controls:6.83%
39
210
274
2920
12
56
301
3074
0
11
313
3119
—
—
10
60
290
3044
44
204
239
2783
hydrocortisone
C05AA01 [21601608]
6.8e-01
7.8e-01
-1.0e+50
—
—
5.6e-01
9.2e-01
cases:12.46%
controls:6.71%
cases:3.83%
controls:1.79%
cases:0.00%
controls:0.35%
—
—
—
—
cases:3.33%
controls:1.93%
cases:15.55%
controls:6.83%
39
210
274
2920
12
56
301
3074
0
11
313
3119
—
—
10
60
290
3044
44
204
239
2783
hydrocortisone butyrate
D07AB02 [21602106]
6.5e-01
8.0e-01
-1.0e+50
—
—
4.7e-01
9.5e-01
cases:11.50%
controls:6.36%
cases:3.83%
controls:1.76%
cases:0.00%
controls:0.35%
—
—
—
—
cases:3.00%
controls:1.90%
cases:15.55%
controls:6.63%
36
199
277
2931
12
55
301
3075
0
11
313
3119
—
—
9
59
291
3045
44
198
239
2789
hydrocortisone aceponate
D07AC16 [21602135]
6.5e-01
8.0e-01
-1.0e+50
—
—
4.7e-01
9.5e-01
cases:11.50%
controls:6.36%
cases:3.83%
controls:1.76%
cases:0.00%
controls:0.35%
—
—
—
—
cases:3.00%
controls:1.90%
cases:15.55%
controls:6.63%
36
199
277
2931
12
55
301
3075
0
11
313
3119
—
—
9
59
291
3045
44
198
239
2789
hydrocortisone buteprate
D07AB11 [21602115]
6.5e-01
8.0e-01
-1.0e+50
—
—
4.7e-01
9.5e-01
cases:11.50%
controls:6.36%
cases:3.83%
controls:1.76%
cases:0.00%
controls:0.35%
—
—
—
—
cases:3.00%
controls:1.90%
cases:15.55%
controls:6.63%
36
199
277
2931
12
55
301
3075
0
11
313
3119
—
—
9
59
291
3045
44
198
239
2789
hydrocortisone
D07AA02 [21602102]
6.5e-01
8.0e-01
-1.0e+50
—
—
4.7e-01
9.5e-01
cases:11.50%
controls:6.36%
cases:3.83%
controls:1.76%
cases:0.00%
controls:0.35%
—
—
—
—
cases:3.00%
controls:1.90%
cases:15.55%
controls:6.63%
36
199
277
2931
12
55
301
3075
0
11
313
3119
—
—
9
59
291
3045
44
198
239
2789
ibuprofen
R02AX02 [1588667]
4.9e-01
4.5e-01
1.1e+00
—
2.0e-01
3.7e-01
1.4e-01
cases:30.35%
controls:21.12%
cases:14.38%
controls:9.71%
cases:4.15%
controls:1.41%
—
—
cases:1.94%
controls:1.60%
cases:14.33%
controls:10.37%
cases:32.51%
controls:29.53%
95
661
218
2469
45
304
268
2826
13
44
300
3086
—
6
50
303
3080
43
322
257
2782
92
882
191
2105
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
4.9e-01
4.5e-01
1.1e+00
—
2.0e-01
3.7e-01
1.4e-01
cases:30.35%
controls:21.12%
cases:14.38%
controls:9.71%
cases:4.15%
controls:1.41%
—
—
cases:1.94%
controls:1.60%
cases:14.33%
controls:10.37%
cases:32.51%
controls:29.53%
95
661
218
2469
45
304
268
2826
13
44
300
3086
—
6
50
303
3080
43
322
257
2782
92
882
191
2105
Ultrasound examination of lower leg veins
PH2AE [2001309451]
1.6e+00
—
—
—
—
—
1.6e+00
cases:1.92%
controls:0.38%
—
—
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.77%
6
12
307
3118
—
—
—
—
—
10
23
273
2964
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.53%
controls:0.77%
—
—
—
—
—
—
10
23
273
2964
pramipexole; oral
N04BC05 [21604477]
2.0e+00
—
—
—
—
—
1.5e+00
cases:1.60%
controls:0.22%
—
—
—
—
—
—
—
—
—
—
cases:4.24%
controls:0.94%
5
7
308
3123
—
—
—
—
—
12
28
271
2959
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.18%
controls:0.70%
—
—
—
—
—
—
9
21
274
2966
More than one and less than three hours
ZXE10 [2001311401]
7.7e-01
1.5e+00
—
—
—
8.6e-01
7.1e-01
cases:6.07%
controls:2.91%
cases:4.15%
controls:0.93%
—
—
—
—
—
—
cases:2.33%
controls:1.00%
cases:7.07%
controls:3.62%
19
91
294
3039
13
29
300
3101
—
—
—
7
31
293
3073
20
108
263
2879
gabapentin; oral
N02BF01 [955005]
1.5e+00
1.6e+00
—
—
—
1.5e+00
1.2e+00
cases:3.51%
controls:0.80%
cases:2.24%
controls:0.45%
—
—
—
—
—
—
cases:2.00%
controls:0.45%
cases:3.89%
controls:1.24%
11
25
302
3105
7
14
306
3116
—
—
—
6
14
294
3090
11
37
272
2950
triamcinolone; nasal
R01AD11 [21605052]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.24%
controls:0.97%
—
—
—
—
—
—
12
29
271
2958
Osmolality of Urine
2695-5 [3026782]
1.4e+00
—
—
—
—
-1.0e+50
1.5e+00
cases:1.60%
controls:0.42%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.26%
cases:5.65%
controls:1.34%
5
13
308
3117
—
—
—
—
0
8
300
3096
16
40
267
2947
Predominantly allergic asthma
J45.0 [45557624]
8.3e-01
—
—
—
—
-1.0e+50
1.5e+00
cases:2.24%
controls:0.99%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.23%
cases:4.24%
controls:1.00%
7
31
306
3099
—
—
—
—
0
7
300
3097
12
30
271
2957
Dentistry
C5 [903277]
1.5e+00
1.6e+00
—
—
—
1.4e+00
—
cases:4.15%
controls:0.99%
cases:2.24%
controls:0.45%
—
—
—
—
—
—
cases:2.00%
controls:0.52%
—
—
13
31
300
3099
7
14
306
3116
—
—
—
6
16
294
3088
—
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
7.0e-01
—
—
—
—
1.4e+00
6.5e-01
cases:2.24%
controls:1.12%
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.81%
cases:8.48%
controls:4.62%
7
35
306
3095
—
—
—
—
10
25
290
3079
24
138
259
2849
antibiotics in combination with corticosteroids
D01AA20 [21601918]
9.8e-01
—
—
—
—
—
1.4e+00
cases:3.83%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:1.24%
12
46
301
3084
—
—
—
—
—
14
37
269
2950
Acute maxillary sinusitis
J01.0 [45601112]
1.4e+00
—
—
—
—
—
3.8e-02
cases:3.19%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:2.12%
controls:2.04%
10
25
303
3105
—
—
—
—
—
6
61
277
2926
tizanidine; oral
M03BX02 [21604116]
8.7e-01
5.1e-01
—
—
1.3e+00
7.8e-01
5.4e-01
cases:19.81%
controls:9.39%
cases:5.75%
controls:3.55%
—
—
—
—
cases:1.94%
controls:0.51%
cases:7.33%
controls:3.51%
cases:19.43%
controls:12.35%
62
294
251
2836
18
111
295
3019
—
—
6
16
303
3114
22
109
278
2995
55
369
228
2618
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.89%
controls:1.00%
—
—
—
—
—
—
11
30
272
2957
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.07%
controls:1.87%
—
—
—
—
—
—
20
56
263
2931
Cystoscopy
UKC02 [2001306005]
1.1e+00
—
—
—
—
—
1.4e+00
cases:2.88%
controls:0.96%
—
—
—
—
—
—
—
—
—
—
cases:4.24%
controls:1.10%
9
30
304
3100
—
—
—
—
—
12
33
271
2954
hydrocortisone; oral, parenteral
H02AB09 [21602737]
1.2e+00
1.4e+00
—
—
—
—
1.4e+00
cases:3.19%
controls:0.99%
cases:1.60%
controls:0.38%
—
—
—
—
—
—
—
—
cases:4.95%
controls:1.31%
10
31
303
3099
5
12
308
3118
—
—
—
—
14
39
269
2948
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.95%
controls:1.31%
—
—
—
—
—
—
14
39
269
2948
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
9.3e-01
—
—
—
—
—
1.4e+00
cases:1.60%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:8.48%
controls:2.31%
5
20
308
3110
—
—
—
—
—
24
69
259
2918
Biopsy of endometrium
LCA06 [2001306551]
—
-1.0e+50
—
—
—
—
1.3e+00
—
—
cases:0.00%
controls:0.26%
—
—
—
—
—
—
—
—
cases:4.24%
controls:1.14%
—
0
8
313
3122
—
—
—
—
12
34
271
2953
Bacteria identified in Blood by Culture
600-7 [3023368]
1.5e+00
—
—
—
—
—
1.3e+00
cases:1.92%
controls:0.42%
—
—
—
—
—
—
—
—
—
—
cases:6.01%
controls:1.64%
6
13
307
3117
—
—
—
—
—
17
49
266
2938
hypromellose
S01KA02 [21605115]
1.1e+00
—
—
—
—
—
1.3e+00
cases:2.88%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
cases:5.65%
controls:1.61%
9
32
304
3098
—
—
—
—
—
16
48
267
2939
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
—
—
—
—
—
1.7e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:2.00%
controls:0.35%
cases:4.95%
controls:1.41%
—
—
—
—
—
6
11
294
3093
14
42
269
2945
Bacteria [Presence] in Urine
87829-8 [36304419]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.36%
controls:1.84%
—
—
—
—
—
—
18
55
265
2932
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.89%
controls:1.10%
—
—
—
—
—
—
11
33
272
2954
Physiotherapist
Z3226 [2001311560]
5.8e-01
9.8e-01
—
—
—
1.1e+00
1.3e+00
cases:1.92%
controls:1.09%
cases:1.60%
controls:0.61%
—
—
—
—
—
—
cases:1.67%
controls:0.58%
cases:7.42%
controls:2.18%
6
34
307
3096
5
19
308
3111
—
—
—
5
18
295
3086
21
65
262
2922
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.42%
controls:2.18%
—
—
—
—
—
—
21
65
262
2922
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
9.3e-01
1.2e+00
—
—
—
—
1.3e+00
cases:1.60%
controls:0.64%
cases:1.60%
controls:0.48%
—
—
—
—
—
—
—
—
cases:6.36%
controls:1.87%
5
20
308
3110
5
15
308
3115
—
—
—
—
18
56
265
2931
beclometasone; inhalant
R03BA01 [21603284]
6.3e-01
8.3e-01
-1.0e+50
—
-1.0e+50
6.3e-01
1.3e+00
cases:4.79%
controls:2.62%
cases:2.88%
controls:1.28%
cases:0.00%
controls:0.26%
—
—
cases:0.00%
controls:0.38%
cases:2.33%
controls:1.26%
cases:7.42%
controls:2.21%
15
82
298
3048
9
40
304
3090
0
8
313
3122
—
0
12
309
3118
7
39
293
3065
21
66
262
2921
alprazolam; oral
N05BA12 [21604577]
1.3e+00
1.1e+00
—
—
—
1.0e+00
8.3e-01
cases:4.47%
controls:1.31%
cases:2.56%
controls:0.83%
—
—
—
—
—
—
cases:2.33%
controls:0.87%
cases:3.18%
controls:1.41%
14
41
299
3089
8
26
305
3104
—
—
—
7
27
293
3077
9
42
274
2945
montelukast; oral
R03DC03 [21603356]
4.1e-01
—
—
—
—
8.1e-01
1.3e+00
cases:1.92%
controls:1.28%
—
—
—
—
—
—
—
—
cases:2.00%
controls:0.90%
cases:6.71%
controls:2.01%
6
40
307
3090
—
—
—
—
6
28
294
3076
19
60
264
2927
triamcinolone and antiseptics
D07BB03 [21602150]
7.1e-01
—
—
—
—
—
1.2e+00
cases:3.83%
controls:1.92%
—
—
—
—
—
—
—
—
—
—
cases:5.65%
controls:1.74%
12
60
301
3070
—
—
—
—
—
16
52
267
2935
ranitidine bismuth citrate; oral
A02BA07 [21600088]
8.2e-01
8.3e-01
-1.0e+50
—
—
1.1e+00
1.2e+00
cases:6.39%
controls:2.91%
cases:2.24%
controls:0.99%
cases:0.00%
controls:0.22%
—
—
—
—
cases:2.33%
controls:0.77%
cases:6.36%
controls:1.98%
20
91
293
3039
7
31
306
3099
0
7
313
3123
—
—
7
24
293
3080
18
59
265
2928
ranitidine; oral, parenteral
A02BA02 [21600083]
8.2e-01
8.3e-01
-1.0e+50
—
—
1.1e+00
1.2e+00
cases:6.39%
controls:2.91%
cases:2.24%
controls:0.99%
cases:0.00%
controls:0.22%
—
—
—
—
cases:2.33%
controls:0.77%
cases:6.36%
controls:1.98%
20
91
293
3039
7
31
306
3099
0
7
313
3123
—
—
7
24
293
3080
18
59
265
2928
General anesthesia, balanced
WX408 [2001310808]
1.2e+00
1.2e+00
—
—
—
1.7e+00
1.2e+00
cases:3.51%
controls:1.12%
cases:1.60%
controls:0.48%
—
—
—
—
—
—
cases:1.67%
controls:0.32%
cases:5.30%
controls:1.64%
11
35
302
3095
5
15
308
3115
—
—
—
5
10
295
3094
15
49
268
2938
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
1.3e+00
1.1e+00
—
—
—
—
1.2e+00
cases:1.92%
controls:0.51%
cases:1.60%
controls:0.54%
—
—
—
—
—
—
—
—
cases:5.30%
controls:1.67%
6
16
307
3114
5
17
308
3113
—
—
—
—
15
50
268
2937
Pain localized to other parts of lower abdomen
R10.3 [45534426]
1.1e+00
—
—
—
—
1.4e+00
1.2e+00
cases:3.51%
controls:1.25%
—
—
—
—
—
—
—
—
cases:1.67%
controls:0.42%
cases:5.65%
controls:1.81%
11
39
302
3091
—
—
—
—
5
13
295
3091
16
54
267
2933
fluticasone; inhalant
R03BA05 [21603288]
1.2e+00
3.9e-01
—
—
—
7.4e-01
4.8e-01
cases:6.07%
controls:1.95%
cases:1.92%
controls:1.31%
—
—
—
—
—
—
cases:2.67%
controls:1.29%
cases:4.24%
controls:2.68%
19
61
294
3069
6
41
307
3089
—
—
—
8
40
292
3064
12
80
271
2907
Leukocytes [#/volume] in Urine
30405-5 [3018095]
—
9.8e-01
—
—
—
1.4e+00
1.2e+00
—
—
cases:1.60%
controls:0.61%
—
—
—
—
—
—
cases:1.67%
controls:0.42%
cases:7.77%
controls:2.54%
—
5
19
308
3111
—
—
—
5
13
295
3091
22
76
261
2911
hydrocortisone and antiseptics
D07BA04 [21602146]
6.6e-01
—
—
—
—
—
1.2e+00
cases:3.51%
controls:1.85%
—
—
—
—
—
—
—
—
—
—
cases:5.30%
controls:1.71%
11
58
302
3072
—
—
—
—
—
15
51
268
2936
chlorhexidine
D09AA12 [21602275]
6.7e-01
—
—
—
—
—
1.2e+00
cases:3.51%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
cases:5.30%
controls:1.71%
11
57
302
3073
—
—
—
—
—
15
51
268
2936
other antifungals for topical use - combinations; ointment
D01AE20 [21601959]
6.7e-01
—
—
—
—
—
1.2e+00
cases:3.51%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
cases:5.30%
controls:1.71%
11
57
302
3073
—
—
—
—
—
15
51
268
2936
chlorhexidine
S03AA04 [21605193]
6.7e-01
—
—
—
—
—
1.2e+00
cases:3.51%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
cases:5.30%
controls:1.71%
11
57
302
3073
—
—
—
—
—
15
51
268
2936
chlorhexidine, combinations
D08AC52 [21602208]
6.7e-01
—
—
—
—
—
1.2e+00
cases:3.51%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
cases:5.30%
controls:1.71%
11
57
302
3073
—
—
—
—
—
15
51
268
2936
hydrocortisone
D07XA01 [21602180]
6.6e-01
—
—
—
—
—
1.2e+00
cases:3.51%
controls:1.85%
—
—
—
—
—
—
—
—
—
—
cases:5.30%
controls:1.71%
11
58
302
3072
—
—
—
—
—
15
51
268
2936
chlorhexidine
S02AA09 [21605155]
6.7e-01
—
—
—
—
—
1.2e+00
cases:3.51%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
cases:5.30%
controls:1.71%
11
57
302
3073
—
—
—
—
—
15
51
268
2936
fluticasone furoate
R03BA09 [45893496]
1.1e+00
—
—
—
—
5.5e-01
4.8e-01
cases:5.11%
controls:1.69%
—
—
—
—
—
—
—
—
cases:2.00%
controls:1.16%
cases:3.89%
controls:2.44%
16
53
297
3077
—
—
—
—
6
36
294
3068
11
73
272
2914
escitalopram; oral
N06AB10 [21604718]
1.1e+00
1.3e+00
—
—
—
1.1e+00
8.2e-01
cases:4.15%
controls:1.37%
cases:3.19%
controls:0.93%
—
—
—
—
—
—
cases:4.00%
controls:1.35%
cases:7.07%
controls:3.25%
13
43
300
3087
10
29
303
3101
—
—
—
12
42
288
3062
20
97
263
2890
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.59%
controls:1.57%
—
—
—
—
—
—
13
47
270
2940
Telephone prescription or other care instructions
WZB00 [2001310884]
1.1e+00
—
—
—
—
1.1e+00
1.1e+00
cases:3.19%
controls:1.12%
—
—
—
—
—
—
—
—
cases:1.67%
controls:0.58%
cases:6.36%
controls:2.28%
10
35
303
3095
—
—
—
—
5
18
295
3086
18
68
265
2919
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
1.1e+00
9.9e-01
—
—
—
1.0e+00
9.6e-01
cases:5.75%
controls:2.08%
cases:2.88%
controls:1.09%
—
—
—
—
—
—
cases:3.00%
controls:1.10%
cases:4.59%
controls:1.81%
18
65
295
3065
9
34
304
3096
—
—
—
9
34
291
3070
13
54
270
2933
salmeterol and fluticasone
R03AK06 [21603280]
1.0e+00
1.1e+00
—
—
—
9.7e-01
8.2e-01
cases:4.47%
controls:1.63%
cases:4.15%
controls:1.47%
—
—
—
—
—
—
cases:3.67%
controls:1.42%
cases:5.65%
controls:2.58%
14
51
299
3079
13
46
300
3084
—
—
—
11
44
289
3060
16
77
267
2910
Dyspnoea
R06.0 [45558449]
1.1e+00
—
—
—
—
—
1.0e+00
cases:3.19%
controls:1.09%
—
—
—
—
—
—
—
—
—
—
cases:6.36%
controls:2.38%
10
34
303
3096
—
—
—
—
—
18
71
265
2916
piroxicam; ointment
M02AA07 [21604043]
5.7e-01
6.6e-01
—
—
-1.0e+50
6.7e-01
1.0e+00
cases:9.58%
controls:5.65%
cases:3.51%
controls:1.85%
—
—
—
—
cases:0.00%
controls:0.35%
cases:2.67%
controls:1.39%
cases:9.89%
controls:3.82%
30
177
283
2953
11
58
302
3072
—
—
0
11
309
3119
8
43
292
3061
28
114
255
2873
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.71%
controls:2.58%
—
—
—
—
—
—
19
77
264
2910
Tissue Pathology biopsy report
66121-5 [40768804]
9.3e-01
—
—
—
—
1.7e+00
9.7e-01
cases:1.92%
controls:0.77%
—
—
—
—
—
—
—
—
cases:2.00%
controls:0.35%
cases:6.01%
controls:2.38%
6
24
307
3106
—
—
—
—
6
11
294
3093
17
71
266
2916
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
5.9e-01
9.2e-01
—
—
—
1.2e+00
9.6e-01
cases:3.51%
controls:1.98%
cases:3.51%
controls:1.44%
—
—
—
—
—
—
cases:4.00%
controls:1.26%
cases:14.84%
controls:6.23%
11
62
302
3068
11
45
302
3085
—
—
—
12
39
288
3065
42
186
241
2801
cefadroxil; oral
J01DB05 [21602874]
9.4e-01
—
—
—
—
—
9.1e-01
cases:9.58%
controls:3.99%
—
—
—
—
—
—
—
—
—
—
cases:3.89%
controls:1.61%
30
125
283
3005
—
—
—
—
—
11
48
272
2939
Pain in limb
M79.6 [45587063]
9.1e-01
1.1e+00
—
—
—
1.0e+00
9.3e-01
cases:2.88%
controls:1.18%
cases:2.24%
controls:0.73%
—
—
—
—
—
—
cases:2.00%
controls:0.71%
cases:7.77%
controls:3.21%
9
37
304
3093
7
23
306
3107
—
—
—
6
22
294
3082
22
96
261
2891
Bacteria identified in Urine by Culture
630-4 [3026008]
1.2e+00
—
—
—
—
1.5e+00
9.3e-01
cases:2.24%
controls:0.70%
—
—
—
—
—
—
—
—
cases:2.00%
controls:0.45%
cases:6.36%
controls:2.61%
7
22
306
3108
—
—
—
—
6
14
294
3090
18
78
265
2909
imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]
3.6e-01
—
—
—
—
—
9.1e-01
cases:4.47%
controls:3.16%
—
—
—
—
—
—
—
—
—
—
cases:7.07%
controls:2.98%
14
99
299
3031
—
—
—
—
—
20
89
263
2898
Otolaryngology
4 [38004449]
5.5e-01
9.1e-01
—
—
1.5e+00
6.6e-01
4.7e-01
cases:14.06%
controls:8.63%
cases:6.39%
controls:2.68%
—
—
—
—
cases:1.62%
controls:0.35%
cases:6.33%
controls:3.38%
cases:14.13%
controls:9.31%
44
270
269
2860
20
84
293
3046
—
—
5
11
304
3119
19
105
281
2999
40
278
243
2709
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
4.9e-01
7.1e-01
—
—
—
6.6e-01
8.9e-01
cases:2.88%
controls:1.79%
cases:2.88%
controls:1.44%
—
—
—
—
—
—
cases:3.00%
controls:1.58%
cases:14.13%
controls:6.36%
9
56
304
3074
9
45
304
3085
—
—
—
9
49
291
3055
40
190
243
2797
mometasone; nasal
R01AD09 [21605051]
3.4e-01
5.9e-02
—
—
1.9e+00
8.8e-01
5.3e-01
cases:8.31%
controls:6.07%
cases:2.88%
controls:2.72%
—
—
—
—
cases:1.94%
controls:0.29%
cases:6.67%
controls:2.87%
cases:13.07%
controls:8.10%
26
190
287
2940
9
85
304
3045
—
—
6
9
303
3121
20
89
280
3015
37
242
246
2745
hydrocortisone
S02BA01 [21605166]
6.7e-01
8.1e-01
-1.0e+50
—
—
2.4e-01
8.8e-01
cases:10.22%
controls:5.50%
cases:3.51%
controls:1.60%
cases:0.00%
controls:0.32%
—
—
—
—
cases:2.33%
controls:1.84%
cases:13.07%
controls:5.86%
32
172
281
2958
11
50
302
3080
0
10
313
3120
—
—
7
57
293
3047
37
175
246
2812
clarithromycin; oral, parenteral
J01FA09 [21602977]
6.7e-01
4.6e-01
—
—
—
—
8.8e-01
cases:6.71%
controls:3.55%
cases:1.92%
controls:1.21%
—
—
—
—
—
—
—
—
cases:9.54%
controls:4.18%
21
111
292
3019
6
38
307
3092
—
—
—
—
27
125
256
2862
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
3.8e-01
7.7e-01
—
—
—
7.4e-01
8.8e-01
cases:2.88%
controls:1.98%
cases:3.19%
controls:1.50%
—
—
—
—
—
—
cases:3.00%
controls:1.45%
cases:14.13%
controls:6.39%
9
62
304
3068
10
47
303
3083
—
—
—
9
45
291
3059
40
191
243
2796
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
5.4e-01
6.5e-01
—
—
-1.0e+50
7.2e-01
8.6e-01
cases:10.86%
controls:6.65%
cases:4.15%
controls:2.20%
—
—
—
—
cases:0.00%
controls:0.38%
cases:3.33%
controls:1.64%
cases:9.89%
controls:4.42%
34
208
279
2922
13
69
300
3061
—
—
0
12
309
3118
10
51
290
3053
28
132
255
2855
Inpatient Visit
IP [9201]
8.6e-01
—
—
—
—
—
3.5e-02
cases:6.39%
controls:2.81%
—
—
—
—
—
—
—
—
—
—
cases:1.77%
controls:1.71%
20
88
293
3042
—
—
—
—
—
5
51
278
2936
isosorbide dinitrate; local oral, oral, sublingual, transdermal
C01DA08 [21600321]
8.5e-01
5.0e-01
—
—
1.2e+00
5.6e-01
3.4e-01
cases:7.35%
controls:3.29%
cases:3.83%
controls:2.36%
—
—
—
—
cases:1.62%
controls:0.51%
cases:4.00%
controls:2.32%
cases:6.71%
controls:4.89%
23
103
290
3027
12
74
301
3056
—
—
5
16
304
3114
12
72
288
3032
19
146
264
2841
INR in Blood by Coagulation assay
34714-6 [3032080]
6.1e-01
—
—
—
—
8.8e-01
8.3e-01
cases:1.92%
controls:1.05%
—
—
—
—
—
—
—
—
cases:2.00%
controls:0.84%
cases:8.13%
controls:3.72%
6
33
307
3097
—
—
—
—
6
26
294
3078
23
111
260
2876
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
5.3e-01
5.9e-01
—
—
—
4.4e-01
8.0e-01
cases:8.31%
controls:5.05%
cases:2.56%
controls:1.44%
—
—
—
—
—
—
cases:2.67%
controls:1.74%
cases:13.07%
controls:6.33%
26
158
287
2972
8
45
305
3085
—
—
—
8
54
292
3050
37
189
246
2798
Cardiology
6 [38004451]
7.7e-01
6.2e-01
—
—
—
4.7e-01
7.9e-01
cases:7.03%
controls:3.39%
cases:3.51%
controls:1.92%
—
—
—
—
—
—
cases:2.67%
controls:1.68%
cases:11.31%
controls:5.46%
22
106
291
3024
11
60
302
3070
—
—
—
8
52
292
3052
32
163
251
2824
acrivastine; oral
R06AX18 [21603518]
7.9e-01
8.9e-01
—
—
-1.0e+50
3.0e-01
4.7e-01
cases:10.54%
controls:5.08%
cases:3.51%
controls:1.47%
—
—
—
—
cases:0.00%
controls:0.16%
cases:2.00%
controls:1.48%
cases:6.71%
controls:4.32%
33
159
280
2971
11
46
302
3084
—
—
0
5
309
3125
6
46
294
3058
19
129
264
2858
metoprolol; oral, parenteral
C07AB02 [21601684]
5.0e-01
7.4e-01
6.3e-02
—
2.1e-01
6.3e-01
4.6e-01
cases:9.27%
controls:5.85%
cases:9.27%
controls:4.66%
cases:1.60%
controls:1.50%
—
—
cases:1.62%
controls:1.31%
cases:8.67%
controls:4.83%
cases:9.54%
controls:6.23%
29
183
284
2947
29
146
284
2984
5
47
308
3083
—
5
41
304
3089
26
150
274
2954
27
186
256
2801
orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]
7.4e-01
7.3e-01
—
—
—
5.8e-01
7.3e-01
cases:7.67%
controls:3.80%
cases:2.56%
controls:1.25%
—
—
—
—
—
—
cases:2.67%
controls:1.51%
cases:10.60%
controls:5.39%
24
119
289
3011
8
39
305
3091
—
—
—
8
47
292
3057
30
161
253
2826
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
7.4e-01
7.3e-01
—
—
—
5.8e-01
7.3e-01
cases:7.67%
controls:3.80%
cases:2.56%
controls:1.25%
—
—
—
—
—
—
cases:2.67%
controls:1.51%
cases:10.60%
controls:5.39%
24
119
289
3011
8
39
305
3091
—
—
—
8
47
292
3057
30
161
253
2826
etoricoxib; oral
M01AH05 [21603996]
7.2e-01
1.2e-01
—
—
—
3.5e-01
7.2e-01
cases:8.63%
controls:4.41%
cases:2.24%
controls:1.98%
—
—
—
—
—
—
cases:3.00%
controls:2.13%
cases:18.02%
controls:9.64%
27
138
286
2992
7
62
306
3068
—
—
—
9
66
291
3038
51
288
232
2699
Ophthalmology
18 [38004463]
6.5e-01
2.6e-01
—
—
—
4.4e-01
4.2e-01
cases:16.93%
controls:9.58%
cases:6.39%
controls:4.98%
—
—
—
—
—
—
cases:7.67%
controls:5.06%
cases:20.49%
controls:14.50%
53
300
260
2830
20
156
293
2974
—
—
—
23
157
277
2947
58
433
225
2554
naproxen; oral, rectal
M01AE02 [21603968]
6.5e-01
3.2e-01
—
—
-1.0e+50
4.9e-01
5.4e-01
cases:16.29%
controls:9.27%
cases:3.51%
controls:2.59%
—
—
—
—
cases:0.00%
controls:0.35%
cases:4.00%
controls:2.48%
cases:11.31%
controls:6.90%
51
290
262
2840
11
81
302
3049
—
—
0
11
309
3119
12
77
288
3027
32
206
251
2781
naproxcinod
M01AE18 [40254094]
6.5e-01
3.2e-01
—
—
-1.0e+50
4.9e-01
5.4e-01
cases:16.29%
controls:9.27%
cases:3.51%
controls:2.59%
—
—
—
—
cases:0.00%
controls:0.35%
cases:4.00%
controls:2.48%
cases:11.31%
controls:6.90%
51
290
262
2840
11
81
302
3049
—
—
0
11
309
3119
12
77
288
3027
32
206
251
2781
bisoprolol; oral
C07AB07 [21601689]
6.4e-01
5.4e-01
2.3e-01
—
1.0e-01
5.8e-01
3.7e-01
cases:15.02%
controls:8.50%
cases:12.46%
controls:7.64%
cases:2.88%
controls:2.30%
—
—
cases:2.27%
controls:2.04%
cases:14.33%
controls:8.57%
cases:17.67%
controls:12.92%
47
266
266
2864
39
239
274
2891
9
72
304
3058
—
7
64
302
3066
43
266
257
2838
50
386
233
2601
General health counselling
SPAT1312 [2001700413]
—
-1.0e+50
—
—
—
—
4.9e-01
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
—
cases:4.24%
controls:2.64%
—
0
11
313
3119
—
—
—
—
12
79
271
2908
Excision of plica of synovy of knee
NGF00 [2001308129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.30%
—
—
—
—
—
—
0
9
283
2978
Nutrition survey
SPAT1139 [2001700240]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.20%
—
—
—
—
—
—
0
6
283
2981
Mitral (valve) prolapse
I34.1 [45552788]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
313
3125
—
—
—
—
—
—
Erythrocyte [DistWidth] in Red Blood Cells by Automated count
788-0 [3019897]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
313
3125
—
—
—
—
—
—
levocetirizine; oral
R06AE09 [21603498]
4.1e-01
—
-1.0e+50
—
—
—
5.5e-01
cases:2.24%
controls:1.50%
—
—
cases:0.00%
controls:0.19%
—
—
—
—
—
—
cases:3.53%
controls:2.08%
7
47
306
3083
—
0
6
313
3124
—
—
—
10
62
273
2925
Pregnancy confirmed
Z32.1 [45566418]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.16%
—
—
—
—
—
—
—
0
5
300
3099
—
Other angina pectoris no detected stenosis of coronary artery
I20.80 [2000502396]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.17%
—
—
—
—
—
—
0
5
283
2982
Other blockage of nerve
WX290 [2001310792]
4.3e-01
—
—
—
—
—
5.7e-01
cases:2.24%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
cases:7.42%
controls:4.35%
7
46
306
3084
—
—
—
—
—
21
130
262
2857
Limited function/disability NOS
A28 [2002000162]
—
—
—
—
—
—
6.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:2.83%
controls:1.54%
—
—
—
—
—
—
8
46
275
2941
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:1.77%
controls:0.40%
—
—
—
—
—
—
5
12
278
2975

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
90
293
3.89
24.16
5.0
1.3
219.20
101.90
ug/g
1.53
75
217
61
267
2.59
9.22
1.9
1.2
—
—
—
0
0
39
143
2.97
8.22
1.4
1.2
—
—
—
0
0
56
270
2.30
6.78
2.5
1.9
388.34
382.13
nmol/l
0.07
50
255
159
1121
1.84
6.58
8.1
4.1
35.92
35.97
g/l
0.04
150
1060
124
826
1.82
6.05
3.8
2.3
57.81
68.08
u/l
0.68
118
768
58
303
2.12
5.74
1.9
1.6
—
—
—
0
0
170
1270
1.73
5.41
4.7
2.9
110.05
103.31
ug/l
0.18
164
1194
183
1399
1.73
5.33
6.0
5.8
10.28
11.05
umol/l
0.30
175
1332
65
367
1.97
5.19
2.4
2.0
—
—
—
0
0
59
323
2.02
5.13
11.6
5.6
1.07
1.04
mmol/l
0.43
54
294
117
799
1.74
5.06
7.9
3.9
7.39
7.40
ph
0.96
97
559
69
403
1.91
4.98
3.8
2.4
2.31
2.31
g/l
0.01
63
370
159
1191
1.67
4.82
3.5
2.5
77.58
77.18
nmol/l
0.05
151
1075
71
426
1.86
4.70
3.9
2.4
12.78
13.46
umol/l
0.27
66
399
65
383
1.88
4.54
1.5
1.3
448.42
502.53
titre
0.13
19
87
121
855
1.67
4.51
9.2
5.1
—
—
—
0
0
110
759
1.69
4.49
4.2
3.0
0.58
0.43
e6/l
0.17
86
542
41
206
2.14
4.47
2.3
3.1
71.66
68.77
e9/l
0.17
31
159
69
419
1.83
4.38
2.1
1.6
—
—
—
0
0
35
167
2.23
4.33
4.4
2.5
228.35
182.84
ng/l
0.23
30
150
80
518
1.73
4.07
2.0
1.7
97143293.49
11415974.10
pmol/l
0.42
70
438
90
607
1.67
3.93
3.7
2.7
5.52
7.40
e6/l
0.58
84
551
171
1357
1.56
3.75
10.3
5.8
0.04
0.04
e9/l
0.06
161
1154
85
571
1.67
3.75
1.4
1.4
2.43
2.34
g/l
0.14
56
349
68
431
1.74
3.71
3.4
2.8
0.82
0.82
mmol/l
0.07
62
407
170
1351
1.56
3.68
10.3
5.7
0.58
0.57
e9/l
0.46
160
1152
46
261
1.89
3.59
5.6
3.5
1.82
1.73
mmol/l
0.06
41
225
172
1376
1.55
3.58
10.3
5.8
2.10
1.97
e9/l
0.24
164
1209
46
265
1.86
3.43
5.6
3.5
7.38
7.39
ph
0.36
30
154
157
1239
1.53
3.43
10.6
5.6
2.96
2.71
%
0.65
150
1158
66
426
1.69
3.36
2.0
1.7
1112.39
1204.13
nmol/l
0.37
51
318
173
1398
1.52
3.36
10.5
6.2
0.21
0.18
e9/l
0.71
166
1216
50
298
1.80
3.35
2.3
1.7
—
—
—
0
0
38
207
1.95
3.35
1.9
2.9
11.09
10.33
g/l
0.49
38
191
89
621
1.60
3.34
7.6
4.9
—
—
—
0
0
156
1236
1.52
3.30
10.8
5.6
0.71
0.69
%
0.27
151
1149
48
286
1.80
3.22
2.2
2.2
6.26
6.66
umol/l
0.05
42
248
176
1437
1.51
3.19
5.7
4.0
0.00
0.00
estimate
-0.00
40
298
48
287
1.79
3.18
6.2
7.0
-0.39
1.04
mmol/l
0.69
33
240
48
289
1.78
3.11
6.8
7.0
7.43
7.41
ph
1.41
28
167
88
623
1.57
3.08
6.0
4.2
1.02
1.02
kg/l
0.60
63
417
184
1524
1.49
3.06
12.5
9.6
4.11
4.05
e9/l
0.15
171
1323
118
896
1.50
2.99
4.5
3.2
16.29
129.99
e6/l
0.90
93
676
155
1245
1.48
2.97
10.8
5.6
8.93
8.69
%
0.48
149
1168
157
1267
1.47
2.92
10.8
5.7
28.26
27.88
%
0.16
152
1200
10
27
3.79
2.90
2.3
1.8
85.44
89.81
%
—
10
27
13
47
2.84
2.85
1.7
1.4
—
—
—
0
0
72
495
1.59
2.84
2.3
2.0
—
—
—
0
0
95
697
1.52
2.81
6.9
3.9
—
—
—
0
0
143
1141
1.46
2.78
2.5
2.1
97.43
96.86
pmol/l
0.05
69
584
143
1141
1.46
2.78
4.9
3.7
6.14
6.18
ph
0.21
85
649
39
229
1.80
2.75
5.3
4.6
0.41
0.85
%
1.14
17
69
75
525
1.56
2.73
5.4
3.6
290.57
371.75
ng/l
0.12
55
397
92
675
1.51
2.71
2.7
2.7
346.73
338.29
umol/l
0.34
75
599
17
73
2.40
2.70
1.4
1.1
—
—
—
0
0
9
24
3.83
2.69
1.0
1.3
—
—
—
0
0
36
208
1.82
2.68
2.0
2.2
0.24
0.22
g/l
1.24
31
191
28
149
1.96
2.66
1.5
3.2
—
—
—
0
0
174
1451
1.44
2.63
5.8
4.0
0.00
0.01
estimate
0.50
37
285
88
645
1.50
2.59
1.5
1.3
0.94
1.54
u/ml
0.63
19
186
147
1191
1.44
2.59
13.1
13.6
1.20
1.24
inr
0.43
128
972
74
523
1.54
2.58
4.7
2.9
504.82
526.11
mosm/kgh2o
0.37
67
455
227
1995
1.49
2.57
12.5
7.3
73.51
78.61
u/l
1.94
219
1889
14
56
2.57
2.56
7.1
3.4
10.79
9.71
pmol/l
0.15
14
56
13
50
2.67
2.56
5.3
2.5
—
—
—
0
0
171
1426
1.43
2.56
5.6
4.0
0.00
0.00
estimate
-0.00
42
291
144
1164
1.43
2.56
9.6
5.8
1.21
1.21
mmol/l
0.13
134
1070
136
1094
1.43
2.46
5.9
3.9
0.06
0.03
estimate
0.18
33
243
17
77
2.28
2.42
4.9
3.7
1.14
2.58
ratio
—
10
42
108
836
1.44
2.39
4.2
3.1
—
—
—
0
0
207
1800
1.43
2.38
7.0
4.4
—
2.61
—
0
5
50
330
1.61
2.33
1.4
1.4
—
—
—
0
0
84
623
1.47
2.31
1.9
1.6
1.11
1.22
mg/l
0.11
61
493
16
72
2.29
2.31
1.4
1.3
287.22
309.12
ug/g
—
9
36
54
364
1.58
2.31
7.5
6.1
104.37
104.11
mmol/l
0.15
54
364
36
219
1.73
2.27
5.4
4.7
0.36
0.10
%
0.78
14
59
16
73
2.26
2.25
1.4
1.3
—
—
—
0
0
10
35
2.92
2.23
1.5
2.0
0.78
0.89
%
—
10
23
34
206
1.73
2.18
2.0
1.4
—
—
—
0
0
35
214
1.71
2.18
5.5
4.6
0.07
0.73
%
2.73
15
59
51
344
1.58
2.17
1.3
1.2
—
—
—
0
0
155
1295
1.39
2.17
12.5
6.7
1.22
1.21
mmol/l
0.23
136
1118
6
14
4.35
2.16
3.0
4.1
365.50
197.14
nmol/l
—
6
14
127
1031
1.39
2.10
5.2
3.8
17.17
87.94
e6/l
3.11
96
709
17
83
2.11
2.05
1.3
1.2
—
—
—
0
0
22
119
1.91
2.03
1.8
1.5
0.18
0.27
mg/l
0.35
12
46
33
203
1.70
2.02
7.4
3.6
108.52
86.50
ng/l
0.59
27
177
36
227
1.66
2.01
5.5
5.2
0.00
0.24
%
0.91
14
59
13
57
2.34
2.00
1.2
1.7
—
—
—
0
0
21
362
0.55
1.92
2.4
3.0
0.81
0.84
ug/l
—
10
217
7
22
3.23
1.89
1.0
1.2
—
—
—
0
0
9
34
2.69
1.88
1.2
1.6
31.67
32.47
pg
—
9
34
8
28
2.90
1.87
4.6
2.4
—
—
—
0
0
14
67
2.14
1.78
1.4
1.1
—
114.29
—
0
7
94
744
1.37
1.77
2.0
1.7
21.41
20.99
nmol/l
0.08
84
631
101
812
1.36
1.72
8.2
6.5
—
—
—
0
0
22
127
1.79
1.69
1.8
2.4
—
—
—
0
0
58
426
1.44
1.67
3.6
2.8
0.80
3.28
e6/l
3.69
29
203
64
479
1.42
1.66
1.5
1.3
14.60
10.66
u/ml
0.11
25
192
69
527
1.40
1.60
1.5
1.3
24.96
28.61
iu/ml
0.19
19
166
6
20
3.04
1.59
1.3
3.9
—
—
—
0
0
13
64
2.08
1.56
1.8
1.3
—
—
—
0
0
11
217
0.49
1.55
1.6
1.9
3.42
3.49
mmol/l
—
5
165
26
162
1.66
1.55
3.9
2.5
—
—
—
0
0
97
792
1.32
1.47
6.5
4.1
0.00
0.01
estimate
0.50
34
271
7
28
2.53
1.46
1.7
1.4
—
—
nmol/l
—
0
0
6
22
2.76
1.44
4.2
4.6
3.42
3.09
nmol/l
—
6
22
6
22
2.76
1.44
1.0
1.1
—
—
—
0
0
143
1234
1.29
1.43
3.5
2.7
—
—
estimate
—
0
0
223
2402
0.76
1.41
4.5
4.2
1.32
1.27
mmol/l
0.44
207
2234
33
224
1.53
1.40
11.9
8.2
—
—
—
0
0
175
1553
1.28
1.40
7.2
4.6
6.64
6.61
mmol/l
0.05
163
1463
229
2452
0.76
1.33
5.6
5.0
5.83
5.92
mmol/l
0.65
214
2272
98
813
1.30
1.31
4.9
3.4
0.03
0.01
estimate
0.24
31
228
18
108
1.71
1.25
1.5
1.8
—
—
—
0
0
99
829
1.28
1.23
5.0
4.1
15.05
8.97
mg/mmol
0.63
59
513
5
19
2.66
1.22
1.0
1.1
—
—
—
0
0
108
916
1.27
1.21
3.9
3.3
2.33
2.36
mmol/l
1.38
98
849
5
20
2.52
1.15
1.0
1.2
111.20
101.95
pmol/l
—
5
20
101
858
1.26
1.10
3.1
2.3
—
—
—
0
0
98
830
1.26
1.10
2.7
2.1
117.68
189.70
u/l
2.14
90
788
8
41
1.98
1.09
1.3
1.2
—
—
—
0
0
12
67
1.82
1.06
2.7
3.0
1.50
2.50
index
—
6
44
95
809
1.25
1.01
3.9
3.4
59.91
54.05
mg/l
0.09
59
517
92
1067
0.81
0.97
3.8
3.1
—
—
—
0
0
115
1006
1.22
0.95
4.6
3.9
57.60
36.32
ng/l
0.31
73
686
6
27
2.24
0.94
2.3
1.3
—
—
—
0
0
245
2569
0.80
0.91
6.1
5.6
2.65
2.74
mmol/l
0.87
230
2409
100
867
1.22
0.90
6.3
3.2
6.44
7.57
mmol/l
1.76
84
741
6
29
2.09
0.90
1.3
1.1
—
—
—
0
0
28
205
1.40
0.87
5.5
3.7
—
—
—
0
0
240
2518
0.81
0.86
5.2
4.9
1.46
1.50
mmol/l
0.85
225
2355
119
1054
1.21
0.86
2.3
2.1
—
—
—
0
0
242
2534
0.81
0.83
5.4
5.0
4.59
4.69
mmol/l
0.84
229
2384
0
24
0.00
0.79
0.0
1.2
—
—
—
0
0
0
26
0.00
0.79
0.0
15.2
—
902.08
—
0
26
268
2772
0.79
0.78
39.4
23.4
131.45
134.52
g/l
2.89
268
2742
229
2169
1.20
0.74
32.5
19.1
13.92
13.62
%
2.17
224
2149
5
25
2.02
0.73
2.4
1.2
—
—
—
0
0
5
25
2.02
0.73
2.0
1.0
—
—
—
0
0
7
39
1.81
0.73
1.4
1.2
—
—
—
0
0
132
1196
1.18
0.72
17.7
11.1
0.00
0.00
e9/l
0.63
119
967
5
26
1.94
0.71
1.2
2.3
11.60
22.08
ug/l
—
5
26
23
305
0.73
0.69
1.6
1.5
—
—
—
0
0
5
27
1.86
0.68
1.2
1.3
14.38
22.36
ng/l
—
5
27
29
225
1.32
0.66
3.0
2.4
6.30
6.15
ph
0.40
22
147
5
29
1.74
0.64
1.2
1.4
—
—
—
0
0
0
20
0.00
0.60
0.0
11.5
—
0.64
—
0
20
0
22
0.00
0.59
0.0
4.6
—
8.15
—
0
22
17
123
1.40
0.59
1.2
1.2
—
—
—
0
0
8
53
1.52
0.59
1.0
1.1
—
—
—
0
0
8
53
1.52
0.59
1.0
1.1
—
—
—
0
0
15
106
1.44
0.59
6.9
1.4
—
—
—
0
0
6
35
1.73
0.58
1.7
1.9
—
—
—
0
0
15
107
1.42
0.56
1.9
1.4
—
—
—
0
0
15
107
1.42
0.56
6.9
1.4
—
—
—
0
0
191
1805
1.15
0.55
4.4
3.2
45.40
45.44
u/l
0.00
183
1715
6
38
1.59
0.54
2.5
1.5
—
—
—
0
0
6
38
1.59
0.54
2.2
1.7
—
—
—
0
0
14
100
1.42
0.52
7.4
1.4
—
—
—
0
0
30
246
1.24
0.47
2.0
2.1
0.00
0.05
estimate
—
7
58
7
49
1.44
0.46
1.0
1.1
—
—
—
0
0
14
103
1.38
0.46
7.4
1.4
—
—
—
0
0
27
222
1.24
0.42
1.1
1.2
—
—
—
0
0
28
232
1.23
0.41
4.0
2.7
0.68
0.55
e6/l
0.09
28
222
5
33
1.52
0.41
1.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
204.43
—
0
16
0
16
0.00
0.41
0.0
2.5
—
8.67
—
0
16
0
18
0.00
0.40
0.0
1.5
—
25.08
—
0
13
6
42
1.44
0.35
1.0
1.0
—
—
—
0
0
29
338
0.84
0.34
1.4
1.3
—
—
—
0
0
13
101
1.30
0.32
4.3
2.1
3025.85
3332.74
u/l
—
6
36
264
2690
0.89
0.29
18.2
11.2
25.65
25.65
u/l
0.00
256
2628
8
62
1.30
0.28
11.5
1.4
—
—
—
0
0
59
540
1.11
0.28
4.5
2.7
2.45
2.45
mmol/l
0.00
53
491
9
77
1.17
0.24
3.8
2.6
—
—
—
0
0
30
266
1.14
0.23
1.4
1.4
—
—
—
0
0
13
106
1.24
0.23
1.3
1.3
104.00
239.67
miu/ml
—
6
48
5
38
1.32
0.23
1.6
1.4
—
—
—
0
0
5
38
1.32
0.23
1.6
1.4
—
—
—
0
0
5
38
1.32
0.23
1.6
1.4
—
—
—
0
0
5
38
1.32
0.23
1.6
1.4
—
—
—
0
0
56
605
0.91
0.23
4.1
4.8
3.64
2.20
ug/l
0.60
48
539
29
257
1.14
0.23
1.7
1.8
—
—
—
0
0
5
39
1.29
0.23
3.4
2.9
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
212
2070
1.07
0.21
5.5
4.5
14.48
14.70
pmol/l
0.74
198
1907
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
0
12
0.00
0.21
0.0
1.0
—
—
—
0
0
21
183
1.16
0.21
1.2
1.2
—
—
—
0
0
6
51
1.18
0.19
1.5
2.0
—
—
—
0
0
13
154
0.84
0.19
1.2
1.1
—
—
—
0
0
10
81
1.24
0.19
6.2
9.8
—
—
—
0
0
10
81
1.24
0.19
1.8
4.0
98.80
222.88
mg/l
—
5
33
25
224
1.13
0.17
1.5
1.4
—
—
—
0
0
21
192
1.10
0.11
1.3
1.3
20.00
162.53
u/ml
—
10
80
12
107
1.13
0.08
5.4
3.1
—
—
—
0
0
238
2403
0.96
0.08
7.3
6.2
39.64
39.19
mmol/mol
0.34
226
2274
8
77
1.04
0.07
1.0
3.2
3.92
4.07
mmol/l
—
8
77
10
112
0.89
0.07
1.3
1.1
—
—
—
0
0
8
78
1.03
0.07
5.8
4.6
—
—
—
0
0
112
1100
1.03
0.06
2.4
1.9
1.51
1.36
mmol/l
1.22
97
933
239
2408
0.97
0.06
6.6
5.5
1.80
1.85
mu/l
0.27
219
2236
74
757
0.97
0.05
1.5
1.4
—
—
—
0
0
256
2568
0.98
0.01
29.1
14.9
19.60
22.53
mg/l
1.12
228
2119
18
174
1.04
0.00
11.9
8.5
1.33
1.38
%
0.07
18
174
10
102
0.98
0.00
1.1
1.1
1.38
1.59
g/l
—
10
102
17
168
1.01
0.00
12.6
8.8
0.70
0.66
%
0.12
17
168
17
168
1.01
0.00
1.5
1.8
—
—
—
0
0
10
103
0.97
0.00
1.1
1.1
0.79
0.91
g/l
—
10
103
6
69
0.87
0.00
3.2
4.4
15.53
29.88
mg/l
—
6
49
8
84
0.95
-0.00
1.8
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
1.97
—
0
6
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.02
—
0
6
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
3.4
—
6.24
—
0
7
0
8
0.00
-0.00
0.0
2.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
135.50
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
13.34
—
0
7
0
9
0.00
-0.00
0.0
1.9
—
14.66
—
0
9
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: COLITENTER – Pseudomembranous colitis

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).